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 The formed elements of blood perform essential functions and are necessary for 
survival. Red blood cells transport oxygen to tissues, platelets maintain hemostasis and 
leukocytes provide host defense. In addition to these autonomous roles, blood cells are 
able to communicate with one another to execute complex physiological processes. 
Platelet interactions with leukocytes and endothelium regulate diverse inflammatory 
responses. Platelet-monocyte interactions result in robust cytokine production in 
monocytes. Neutrophils receive signals from platelets which can result in transendothelial 
migration or neutrophil extracellular trap (NET) formation. Many of the mechanisms by 
which these processes are regulated have only been recently discovered. Here we report 
that platelets are able to sequester exogenous ribonucleic acid (eRNA). This uptake is 
time and dose dependent and is unique to platelets of the cells examined so far. Uptake of 
eRNA does not require activation of platelets or alter the ability of platelets to respond to 
thrombin. While the fate of this sequestered eRNA has yet to be determined, our 
observations represent the first report of this novel capacity of platelets. Our interest in 
platelet and leukocyte biology also led us to develop a genetic screen to identify genes 
required for NET formation. The nearly haploid human cell line, KBM-7, was 
determined to be competent to form NETs, and a retroviral gene-trap mutagenesis 
strategy was employed to generate a pool of mutants to assay for defects in NET 
formation. Due to technical limitations, the screen was unable to be executed as designed, 
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but advances in bioinformatics may allow a modified version of the screen to be 
performed in the near future. Throughout the body of this work, we have used traditional 
techniques combined with modern innovations to interrogate the functions of platelets 
and leukocytes. The knowledge gained in these investigations will improve our 
understanding of these essential cells and provide new avenues for research and 












































1 INTRODUCTION ................................................................................................................. 1 
 
The Formed Elements of Blood ....................................................................................... 1 
Platelets: Central Mediators of Hemostasis and Inflammation ...................................... 2 
Leukocytes: Genetic Deficiencies Illuminate Mechanisms of Immunity ..................... 6 
Neutrophils: Leukocytes Specialized for Rapid Defense ............................................... 8 
Modern Tools and Approaches for Cell Biology .......................................................... 10 
References ....................................................................................................................... 12 
 
2 PLATELETS SEQUESTER EXOGENOUS RNA .......................................................... 18 
 
Abstract ............................................................................................................................ 18 
Introduction ..................................................................................................................... 19 
Materials and Methods ................................................................................................... 22 
Results.............................................................................................................................. 28 
Discussion........................................................................................................................ 46 
References ....................................................................................................................... 49 
 
3 A GENETIC SCREEN TO IDENTIFY NOVEL FACTORS FOR NEUTROPHIL 
EXTRACELLULAR TRAP FORMATION ........................................................................ 56 
 
Abstract ............................................................................................................................ 56 
Introduction ..................................................................................................................... 57 
Materials and Methods ................................................................................................... 61 
Results.............................................................................................................................. 66 
Discussion........................................................................................................................ 79 




4 DISCUSSION ...................................................................................................................... 85 
 
       Current Review of Platelet Biology ............................................................................... 85 
Platelets and eRNA ......................................................................................................... 88 
Neutrophil Extracellular Traps: Then, Now and Tomorrow ........................................ 93 






A: LEUKOCYTE ADHESION DEFICIENCY-I VARIANT SYNDROME (LAD-Iv, 
LAD-III): MOLECULAR CHARACTERIZATION OF THE DEFECT IN AN 
INDEX FAMILY ..........................................................................................................110 
 




































1.1: Platelets integrate a variety of inputs to mediate pathology in systemic inflammatory 
responses ...................................................................................................................................4 
 
2.1: Exogenous RNA tagged with a fluorescent aptamer is taken up by platelets. .......... .29 
 
2.2: Exogenous RNA labeled with Alexa-488 is visible within the granulomere of spread 
platelets. ................................................................................................................................ .31 
 
2.3: Timecourse of RNA uptake by platelets...................................................................... .33 
 
2.4:Concentration response of RNA uptake by platelets. .................................................. .34 
 
2.5: Exogenous RNA uptake is unique to platelets. ........................................................... .36 
 
2.6: Platelets exposed to eRNA translocate P-selectin to their membrane in response to 
thrombin normally. ............................................................................................................... .39 
 
2.7: Platelets exposed to eRNA bind PAC-1 in response to thrombin normally. ..............40 
 
2.8: Platelets appear to express protein from eRNA by western blot analysis. ................ .42 
 
2.9: Platelets appear to express protein from eRNA by immunocytochemistry. ............. .43 
 
2.10: Induced band in platelets is not RFP. ........................................................................ .44 
 
3.1: FACS sorting of KBM-7 cells enriches for haploid population. ............................... .67 
 
3.2: KBM-7 cells make NETs. ............................................................................................ .69 
 
3.3: Extracellular DNA quantitation by Picogreen plate assay. ..........................................72 
 
3.4: Puromycin kill curve of KBM-7 cells.......................................................................... .74 
 
3.5: Flow cytometry detects GFP expression in transduced Phoenix cells. ..................... .76 
 
3.6: GFP is detectable in genomic DNA of transduced KBM-7 cells by PCR ................ .78
ix 
 
4.1: Kindlin-3 is absent in EBV-transformed lymphoblasts from Patient 1. ................... 100 
 
A.1: Leukocytes from Patient 2 demonstrated the LAD-1v/LAD-III phenotype of 
impaired inside-out signaling of β1 and β2 integrins…………........................................112 
 
A.2: Monocytes from Patient 2 did not adhere or differentiate in culture……………...112 
 
A.3: KINDLIN-3 is absent in EBV-transformed lymphoblasts from Patient 1………...112 
 












 The work presented in this dissertation represents the tireless efforts of many 
people that helped me develop as a scientist and critical thinker. My mentor, Andy 
Weyrich, has been a source of enthusiastic support and provided a challenging laboratory 
environment that taught me diverse scientific and leadership skills. In the lab, Hansjorg 
Schwertz contributed to my platelet work directly with experimental collaboration and 
technical expertise and indirectly by sharing his boundless enthusiasm for platelet 
biology. Con Yost generously shared reagents and expertise regarding neutrophil 
extracellular trap biology to advance the genetic screen project. I would like to thank 
Donelle Benson and Jessica Phibbs for their phlebotomy and cell isolation and culture 
skills, as well as their unique perspectives and encouragement throughout my tenure in 
the lab. Finally, I’d like to acknowledge Neal Tolley for his broad interest in biology and 
science, which served as a foil for many interesting discussions and diversions that 
allowed me to think around corners and develop projects that seemed hopelessly stalled.  
 My thesis committee members, including Andy Weyrich, Curt Hagedorn, Gerald 
Spangrude, Janis Weis and Guy Zimmerman have provided thoughtful suggestions 
throughout the years and sharpened and shaped my thinking as a scientist, for which I am 
grateful. Outside of committee meetings, these people as well as countless others in the 
University community have served as a valuable sounding board and helped me grow 
professionally and personally. 
xi 
 
 The University of Utah MD PhD training program and the Hematology Training 
Grant have provided funding for my work, which I would like to thank them for. Jerry 
Kaplan, who has been responsible for the MD PhD program during my tenure with the 
program is a scientific titan and has created a program that brings together diverse people 
to train physician scientists while still demonstrating a personal investment in the success 
of each of these students. Janet Bassett keeps the cogs of the MD PhD machine greased 
and without her efforts this program would surely grind to a halt.  
 I need to thank the American Journal of Hematology for permission to use the 
following article: Harris E, Smith T, Springett G, Weyrich A, Zimmerman G. Leukocyte 
adhesion deficiency-I variant syndrome (LAD-Iv, LAD-III): molecular characterization 
of the defect in an index family. American Journal of Hematology. 2012;87(3):311-3. 
 I need to thank the journal  Thrombosis Research for permission to use the 
following article: Smith TL, Weyrich AS. Platelets as Central Mediators of Systemic 
Inflammatory Responses. Thrombosis Research. 2011;127(5):391-394. 
 Finally, I would like to thank the family and friends who have supported me 
during this adventure. My life would be a pale shadow of what it is without the color and 
light all of these people add to my days. My partner, Brian, makes all things possible with 













The Formed Elements of Blood 
 Blood is an essential vertebrate tissue consisting of plasma and formed elements. 
The formed elements of blood include red blood cells (RBCs), platelets and leukocytes. 
While each of these elements executes specialized functions on their own, they also 
communicate with one another as well as various tissues throughout the body to 
orchestrate complex physiological processes. Understanding the behavior of these formed 
elements in isolation and in concert with one another is critical for deciphering their 
contributions to both health and disease. 
 The study of the formed elements of blood was impossible before the advent of 
microscopy. The first recorded observation of a blood cell was of an RBC by Jan 
Swammerdam in 16581. Leukocytes and platelets were not observed until the mid-1800s, 
a lag explained by the relative abundance of RBCs to platelets and white blood cells 
(WBCs). Not long after their discovery, the primary function of each of these 
components was described. The majority of an RBC is composed of hemoglobin, a 
molecule whose reversible oxygenation was characterized by Felix Hoppe-Seyler in the 
second half of the 19
th
 century2. The ability of platelets to accumulate at the site of 
vascular injury was described by Bizzozero in the late 1800s3. Leukocytes, a diverse 
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group of cells within themselves, were not readily distinguished from one another until 
Paul Ehrlich published a method for staining blood films in 18791. The distinction 
between granulocytes, lymphocytes and monocytes allowed for understanding the distinct 
role each of these leukocyte subsets plays in innate and adaptive immunity. 
 While direct microscopic observation provided a wealth of information to early 
hematologists, the past few decades have given researchers the biochemical, molecular 
and genetic tools to expand the limits of our understanding of the biology of these formed 
elements of blood. Platelets, far from simply creating hemostatic plugs, have been shown 
to participate in inflammatory processes with other cells throughout the body4,5. The 
study of rare hereditary immunodeficiencies not only led to identification of the 
mutations responsible for the leukocyte defects, but also to a broader understanding of 
common cell signaling processes6,7. Neutrophils, cells long recognized for their 
importance in killing invading organisms, have only recently revealed their ability to kill 
microbes using extracellular DNA traps8. Continued interrogation of each of these 
formed elements in isolation and in concert will enable better understanding of the human 
organism as a whole and provide novel therapeutics to improve health. 
 
Platelets: Central Mediators of Hemostasis and Inflammation 
 Platelets, the smallest of the formed elements, were easily overlooked in early 
microscopic studies of blood. When they were noted, they were thought to represent 
degraded leukocytes or precursors to erythrocytes9. This debate was settled by Giulio 
Bizzozero’s careful microscopic examination of blood both in vivo and in vitro, 
whereupon he firmly declared platelets to be the third element of blood, along with RBCs 
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and WBCs. Bizzozero observed the rapid accumulation of platelets in injured blood 
vessels, as well as characterized the deposition of platelets followed by fibrin on foreign 
surfaces, providing one of the earliest descriptions of thrombus formation 3.  
 Thirty years after these seminal observations on the function of platelets, James 
Wright demonstrated that platelets arise from fragmented megakaryocytes within the 
bone marrow10. Megakaryocytes are terminally differentiated cells which undergo a 
process of endomitosis before elaborating their cytoplasm and membranes to produce 
proplatelets11. During this process, proplatelets are packaged with organelles such as 
mitochondria, alpha and dense granules, ribonucleic acid (RNA), proteins and 
cytoskeletal components. Megakaryocytes do not indiscriminately partition their 
cytoplasmic constituents into proplatelets, but selectively transfer a subset of these into 
the nascent proplatelet12. The importance of proper trafficking of these components is 
underscored by the variety of rare platelet disorders caused by genetic defects in 
cytoskeletal and sorting proteins13-15. Global analysis of the platelet transcriptome and 
proteome has demonstrated little variation between healthy donors16,17. However, platelets 
from diseased patients show altered RNA and protein signatures, suggesting that platelet 
constituents are dynamically regulated in response to physiological cues18-21. Whether this 
regulation occurs as platelets are produced by megakaryocytes in the bone marrow or 
represents alterations acquired as platelets circulate within the periphery remains to be 
determined. 
 Extracellular cues affect changes within individual platelets in addition to the 





Figure 1.1. Platelets integrate a variety of inputs to mediate pathology in systemic 
inflammatory responses. Thrombin, PAF, and microorganisms are commonly observed in 
infectious situations. Each of these factors modulates platelet function, inducing both 
rapid and prolonged responses that include the formation of homotypic and heterotypic 
aggregates. Platelet-platelet aggregates and platelet-leukocyte aggregates contribute to 
DIC, the formation of NETs, and the synthesis and secretion of proinflammatory 
cytokines that are commonly observed as the host responds to infection. These responses 
may help fight off infection, but they can also contribute to the pathology of the disease. 
Abbreviations: DIC, disseminated intravascular coagulation; NETs, neutrophil 
extracellular traps; PAF, platelet activating factor; PAFR, PAF receptor; PAR, protease 
activated receptor; TLR, Toll-like receptor.
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rapid degranulation of platelets and release of vasoactive and prothrombotic factors22,23, 
important responses to maintain hemostasis following damage to vessels. These rapid and 
conspicuous changes overshadowed more long term consequences of platelet activation 
for years. In the late 1990s, thrombin-activated platelets were shown to synthesize Bcl-3 
rapidly, but also to sustain this response for up to 8 hours24. Synthesis of Bcl-3 is required 
for normal retraction of fibrin clots to support recanalization of vessels and reperfusion of 
tissues after injury25. Anucleate platelets also contain precursor mRNAs, which they are 
capable of splicing and translating in response to activating signals26-28. In the case of IL-
1β synthesis by activated platelets, the subsequent release of this inflammatory mediator 
promotes adherence of neutrophils to the endothelium28.  
 Activated platelets promote inflammation through interactions with other cells in 
addition to the cell autonomous mechanisms described above. Platelet binding to 
monocytes promotes nuclear translocation of NF-κB and proinflammatory cytokine 
production, such as MCP-1 and IL-8, by monocytes29. The induction of COX-2 
expression in monocytes by platelets is regulated by an additional posttranscriptional 
checkpoint requiring COX-2 mRNA stabilization downstream of IL-1β signaling, 
allowing for tightly regulated synthesis of this protein30. Platelet signals to neutrophils 
can promote extracellular trap formation in a TLR4-dependent manner, an important 
innate immune response which will be described in further detail later31. Cytokines 
secreted by platelets signal to endothelium to promote leukocyte adhesion, amplifying 
existing inflammation in a site-specific manner32. Taken together, it is clear that platelets 
serve not only as important mediators of hemostasis, but also as central regulators of 
inflammatory responses. Deciphering the mechanisms by which these anucleate 
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cytoplasts communicate with such diverse cells may provide new targets for therapeutics 
in the future. 
 
Leukocytes: Genetic Deficiencies Illuminate Mechanisms of Immunity  
 Leukocytes are the most heterogeneous of the formed elements of blood. 
Leukocytes found in peripheral blood consist of neutrophils, monocytes and 
lymphocytes. While each of these cells has their own unique characteristics, they are all 
involved in immune defense. As such, the ability of leukocytes to traffic to sites of 
inflammation to mediate effector functions is fundamental. Rare genetic defects known as 
leukocyte adhesion deficiencies (LAD) have provided important insights into the steps 
required for leukocytes to adhere to activated endothelium, known as the adhesion 
cascade6. In addition, these maladies have illuminated common themes used for 
intercellular and intracellular communication. 
 The initial step of the adhesion cascade requires leukocytes to loosely adhere to 
the endothelium in a process known as rolling, which is mediated by selectins33. Inflamed 
endothelial cells express E-selectin and P-selectin, which interact with fucosylated P-
selectin glycoprotein ligand-1 (PSGL-1) on leukocytes to induce rolling34,35. A genetic 
mutation resulting in defective GDP-fucose transport into Golgi vesicles leads to global 
disruption of fucosylated glycoconjugates and the immunodeficiency known as LAD-
II36,37. Hallmarks of LAD-II include recurrent infections, severe mental retardation, short 
stature and facial stigmata38. While the immune deficiency is explained by the lack of 
selectin ligands on leukocytes, the metabolic pathways contributing to the remainder of 
the phenotype remain unclear and continue to be the subject of study39. 
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 The importance of integrin signaling for firm adhesion of leukocytes to activated 
endothelium is underscored by the fact that mutations in the gene ITGB2, coding for the 
β2 integrin subunit, lead to LAD-1. These mutations result in absent, reduced or 
nonfunctional expression of β2 integrin on the surface of leukocytes. While still rare, 
LAD-1 is the most common of the leukocyte adhesion deficiencies, with over 80 
mutations described in the ITGB2 gene resulting in moderate to severe phenotypes40. 
Clinically, delayed separation of the umbilical cord, severe bacterial infections and the 
absence of pus formation at sites of infection are hallmarks of LAD-I39,41. The absence of 
viral infections in these patients illustrates the fact that lymphocytes are able to use β1 
integrin-dependent adhesion for transendothelial migration, while neutrophils and 
monocytes rely on β2 integrin
42. 
 The genetic defect responsible for LAD-III is the most recent to be characterized, 
and represents an important breakthrough in understanding integrin-mediated inside-out 
signaling 43. Patients with LAD-III have normal surface expression of integrin 
heterodimers, yet suffer from recurrent bacterial and fungal infections as well as a severe 
bleeding tendency due to a platelet defect44-46. This compound phenotype affecting the 
function of β1, β2 and β3 integrins without compromising their expression suggested a 
defect in a common integrin tail binding protein39. The search for this protein ultimately 
led to the identification of Kindlin-3, which is localized to integrin adhesion sites and 
expressed primarily in hematopoietic cells47. Deletion of Kindlin-3 in mice phenocopies 
defects seen in LAD-III patients48. Genotyping of the index patients rapidly confirmed 
that mutations in the FERMT3 gene, which codes for Kindlin-3, were responsible for 
LAD-III in all of the reported families7,49-52. Kindlin-3 binds to the cytoplasmic tail of β 
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integrins, facilitating the conformational change of αβ heterodimers required for inside-
out integrin signaling in platelets, neutrophils and lymphocytes53. Whether Kindlin-3 
serves as a cofactor, scaffold protein or regulates integrin affinity or avidity is the subject 
of ongoing research54. While the molecular details are not yet clear, LAD-III provides an 
example of how careful observation of complex clinical phenotypes and animal models 
can provide insights into fundamental cell biology.    
 
Neutrophils: Leukocytes Specialized for Rapid Defense 
 Neutrophils are the most abundant leukocytes found in peripheral blood and are 
widely accepted to provide first-line defense against pathogens. Inflammatory cytokines 
activate neutrophils, resulting in interaction with selectins and integrins on the 
endothelium and allowing them to escape the circulation and traffic to sites of infection55. 
Genetic defects affecting this process can result in severe immunodeficiencies (described 
above). Migration of neutrophils to sites of injury after traversing the endothelial barrier 
depends on chemoattractant gradients55. 
 Upon encountering pathogens, neutrophils use several strategies to protect the 
host. In the early 20
th
 century, Elie Metchnikoff reported phagocytic killing of 
pathogens56. This receptor-mediated engulfment of pathogens results in the formation of a 
phagosome within the neutrophil57. Granules stored within neutrophils contain hydrolytic 
enzymes and antimicrobial proteins, capable of fusing with the phagosome to effect 
cytotoxic  killing58. These granules may also be released from neutrophils to kill 
extracellular pathogens. In addition to the preformed antimicrobial agents present within 
granules, neutrophils produce highly cytotoxic reactive oxygen species (ROS) upon 
 
9 
activation59,60. Genetic defects in any of the subunits of the NADPH oxidase enzyme 
required to generate this “oxidative burst” result in the immune deficiency known as 
chronic granulomatous disease (CGD)61-63. Patients with CGD suffer from recurrent 
infections due to an inability to generate an oxidative burst to kill phagocytosed 
organisms. In addition, CGD patients are unable to generate neutrophil extracellular traps 
(NETs), a recently described tool by which neutrophils ensnare and kill extracellular 
organisms8. 
 NETs form when stimulated neutrophils undergo an active form of cell death, 
known as NETosis, which is distinct from apoptosis and necrosis64. During NETosis, the 
nuclear membrane disintegrates and chromatin decondenses, mixes with cytoplasmic 
granules, and is released from the cell8,64. This process has been shown to trap and kill 
bacteria, fungi and protozoan parasites65. Neutrophils isolated from patients with CGD 
are unable to form NETs in response to stimuli unless treated with supplemental ROS, 
demonstrating that the enzyme activity of NADPH oxidase is required for this process64. 
Gene therapy to replace the defective subunit of NADPH oxidase in a patient with CGD 
restored NET formation and resulted in clearance of a fulminant Aspergillus infection66. 
Importantly, Aspergillus hyphae cannot be effectively phagocytosed by neutrophils, 
suggesting that NET-mediated killing is required to control these infections.  
 As with all weapons, misuse can be destructive. Failure of neutrophils to properly 
clear after recruitment can lead to chronic inflammation. Deregulated neutrophil 
clearance has been implicated in the pathogenesis of autoimmune disorders such as 
rheumatoid arthritis, autoimmune vasculitis and systemic lupus erythematosus (SLE)67-69. 
The lungs of patients with chronic obstructive pulmonary disease show chronic 
 
10 
neutrophil infiltrates with concomitant tissue damage and dysfunction70. NETs, only 
discovered a decade ago, have been implicated in acute lung injury and organ damage in 
sepsis31,71,72. While neutrophils are capable of providing rapid defense against pathogens, 
tight control of the weapons in their arsenal is necessary to prevent damage to the host. 
Understanding the balance between protection and destruction is an important 
consideration when targeting these powerful cells clinically. 
 
Modern Tools and Approaches for Cell Biology 
 The tools available to study the formed elements of blood have come a long way 
since the first look at red blood cells under a simple microscope. Confocal microscopy 
and fluorescently labeled antibodies allow for specific staining of subcellular structures 
and high resolution imaging. The revolution of molecular biology enables rapid 
identification of specific mutations in genes as well as quantitation of the entire 
transcriptome of a given sample. Thorough clinical characterization of patients with rare 
heritable diseases combined with molecular techniques provides insight into normal 
cellular functions. Due to the complexity of multicellular organisms, many genes 
required for hematopoiesis are required for earlier development, and defects in these 
genes are not compatible with life. One technique which may allow interrogation of such 
genes is gene-trap mutagenesis in cell lines. 
 Gene-trap mutagenesis introduces an engineered vector into the genome of target 
cells by electroporation or retroviral infection73. This vector is designed with a splice 
acceptor site upstream of a promoterless reporter (such as GFP)74. Upon successful 
integration into a gene, transcriptional activation from the endogenous promoter results in 
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expression of a fusion transcript consisting of the upstream coding sequence and the 
reporter gene. Successful mutagenesis can be tracked via expression of the reporter, 
which also serves as a template for PCR-based cloning of the insertion site within the 
genome. High throughput sequencing technology allows for identification of millions of 
mutant alleles within a pool of mutagenized cells, and subsequent identification of 
candidate genes required for the observed phenotype75. Gene-trap mutagenesis only 
results in disruption of a single allele and diploid mammalian genomes still express one 
functional copy of the targeted gene after mutagenesis. With the exception of disrupted 
gene products which have a dominant negative effect on the function of the endogenous 
gene product, such screens are of limited utility in diploid cells. Interestingly, a mostly 
haploid human cell line is available and has been used successfully for gene trap 
mutagenesis screens76,77. The availability of technologies such as gene-trap mutagenesis 
in human cells and high-throughput sequencing may hold the keys to identifying the 
function of countless new genes important for health and disease. 
 We have taken advantage of these modern tools and approaches to interrogate the 
functions of platelets and leukocytes and to better understand these formed elements. 
Using confocal microscopy and molecular techniques, we characterize for the first time 
the ability of platelets to sequester exogenous RNA. Gene-trap mutagenesis provided the 
inspiration behind a genetic screen to identify factors required for NET formation. 
Through sequencing and western blotting, as well as cell culture techniques, we 
confirmed that a mutation in FERMT3 was responsible for LAD-III in the family we had 
previously identified7,46. This body of work serves to answer some fundamental questions 
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about the biology of blood cells while laying a foundation for new questions to be asked 
and progress to be made toward improving health for future generations.  
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PLATELETS SEQUESTER EXOGENOUS RNA 
 
Abstract 
Platelets have long been appreciated for their role in maintaining hemostasis and 
contributing to thrombosis. Increasingly, new roles for platelets are emerging. The ability 
of platelets to respond to stimuli and translate messages accordingly has been 
demonstrated. In addition, it is evident that platelets circulating in an inflammatory milieu 
such as sepsis have altered mRNA and protein expression patterns when compared to 
basal conditions. Interactions with other vascular and immune cells also provide a 
platform by which platelets convey information and affect function within the body. Here 
we describe a novel function of platelets: the sequestration of exogenous RNA. Using 
human platelets, monocytes, THP-1 cells and umbilical vein endothelial cells we have 
shown that this uptake is unique to platelets and represents a previously unrecognized 
function of this anucleate cytoplast.  The kinetics of RNA uptake show a reproducible 
peak at 2h, and are concentration dependent. RNA is taken up and sequestered within the 
granulomere of platelets and is not translated under conditions we have tested. Basic 
platelet functions, including the ability to adhere to matrix, express surface P-selectin, or 
undergo conformational changes in αIIbβ3 integrin are unaffected by interaction with 
exogenous RNA in the presence or absence of thrombin. These data serve to characterize 
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this novel function of platelets and provide the groundwork for future studies to 
determine the role of platelet RNA uptake in health and disease. 
 
Introduction 
Platelets were first observed at sites of vascular injury by Bizzozero in the late 
1800s1. Over the next century, the critical role that platelets play in maintaining 
hemostasis and in maladies such as stroke and myocardial infarction has been elucidated 
and oral antiplatelet drugs have become a $15 billion a year industry2. More recently, 
platelets have been recognized as effectors of immune function3, and future research 
promises to bring new properties of platelets to light. 
Platelets are the progeny of megakaryocytes, which reside primarily in the bone 
marrow. Upon the initiation of proplatelet formation long cytoplasmic extensions 
protrude from the body of the progenitor into venous sinusoids4. Organelles including 
mitochondria, alpha and dense granules, proteins and RNA traffic from the body of the 
megakaryocyte to these cytoplasmic extensions, which pinch off to become 
proplatelets5,6. Data suggests that the final stages of platelet maturation occur, in part, in 
the circulation7,8. The end result is the release of individual, discoid platelets that are 
packed with organelles and cytoskeletal elements. While platelets are devoid of a 
nucleus, they are capable of a wide range of complex cellular processes, including 
processing of pre-mRNA to form a mature transcript9-11, translation12-14, and anuclear cell 
division that resembles proplatelet formation in megakaryocytes15. The execution of these 
events serves to diversify the functional repertoire of platelets in response to 
environmental cues.  
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Homotypic aggregates of platelets form as fibrinogen binds activated integrin 
αIIbβ3 receptors on the surface of platelets
16. This is an important step in hemostasis, as 
patients with genetic defects in αIIbβ3 (Glanzmann’s thrombasthenia) have profound 
bleeding disorders17. Platelets also use regulated surface expression of receptors to 
interact with other cells, including monocytes and neutrophils18-20. These heterotypic 
interactions have been shown by our lab and others to induce functional changes within 
these cells. For example, platelet interaction with monocytes through a P-selectin/PSGL-
1-dependent mechanism induces nuclear translocation of NF-κB and proinflammatory 
cytokine production, as well as upregulation of integrins which promote adhesion to 
activated endothelium21,22. Activated platelets induce transcription of COX-2 mRNA in 
monocytes rapidly, but this message is only translated after receiving a secondary IL-1β 
signal from platelets which stabilizes the transcript23. Platelets also adhere to activated 
endothelium to promote transendothelial migration of neutrophils through interactions 
with P-selectin, PSGL-1 and Mac-124,25. Taken together, these data and others suggest that 
platelets are not exclusively cell autonomous, but orchestrate complex interactions with 
other cells to maintain hemostasis and coordinate inflammatory responses.  
 Clinically, the role of platelets as biomarkers of disease is increasingly 
appreciated in addition to their functional properties. Heterotypic aggregates of platelets 
and leukocytes have been shown to be a more sensitive marker of platelet activation than 
P-selectin expression26, and can be used to stratify patients with acute myocardial 
infarction27,28. Surprisingly, platelets have also been reported to contain mutant RNA from 
tumors. Specifically, a study by Nilsson et al. demonstrated that platelets from glioma 
patients contain tumor-derived mutant RNA and that this RNA is transferred in vitro via 
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membrane microvesicles29. As platelets are more readily available for diagnostic testing 
than glioma biopsies, they may play an important role in personalized medicine and 
predicting tumor response to therapy.  
 Tumor-associated RNA has also been reported within the serum of patients with 
melanoma30, breast cancer31 and nasopharyngeal carcinoma32. This is surprising given the 
abundant ribonuclease activity present within human plasma33, but may represent a 
protected fraction of RNA bound by proteolipids or other macromolecules34. In addition 
to serving as a marker of disease, extracellular RNA can directly mediate the 
permeability of the vascular endothelium in an VEGF-dependent manner, and 
pretreatment with RNase reduces vessel occlusion and edema in animal models of 
stroke35,36. Proteases important for the contact phase of blood coagulation (Factors XII 
and XI) bind extracellular RNA and have increased activity (˜40-fold) in the presence of 
RNA37. This ability of extracellular RNA to potentiate coagulation responses may play a 
role in hemostasis in response to massive tissue damage, where lysed cells release their 
contents into the extracellular space.  
Here we report that platelets are able to sequester exogenous RNA (eRNA). Using 
platelets isolated from human donors, we demonstrate that eRNA uptake is time—and 
concentration—dependent, and unique to platelets of the cells examined so far. Uptake of 
eRNA does not require activation of platelets, and occurs independent of transcript size 
or secondary structure. Microscopy studies allowed us to visualize eRNA within the 
granulomere of spread platelets after uptake. Platelets exposed to eRNA are able to 
adhere to fibrinogen, express P-selectin on their surface and bind PAC-1 upon 
stimulation with thrombin, suggesting that eRNA uptake by platelets does not trigger 
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traditional platelet activation. The fate of this sequestered eRNA has yet to be 
determined, as we have not detected translation under conditions tested thus far. Given 
the recently described role of eRNA in potentiating coagulation37, it is intriguing to 
speculate that platelets may scavenge eRNA from the circulation to prevent spurious 
thrombus formation. Work to test this hypothesis is ongoing. For now, these data serve to 
characterize this novel function of platelets and, in doing so, provide the groundwork for 
future studies to determine the physiological role of this process. 
 
Materials and Methods 
Cell isolation and culture 
All studies were approved by the University of Utah Institutional Review Board 
committee (IRB #392). Leukocyte-depleted platelets were isolated as previously 
described10. Platelets were resuspended at 100,000/µL in serum-free M199 medium, 
placed in round-bottom polypropylene tubes and cultured in a 37°C humidified incubator 
with 5% CO2. Monocytes were isolated from a Ficoll monolayer using CD14
+
 beads 
(Miltenyi Biotec, Auburn, CA) and resuspended at 1000/µL in serum-free M199 
medium, and cultured as described for platelets. THP-1 cells were obtained from and 
propagated as indicated by the distributor (ATCC, Manassas, VA, batch ID 38999776).  
For experiments, THP-1 cells were centrifuged, washed once in Hank’s Balanced Salt 
Solution (HBSS), resuspended in M199 and cultured under the same conditions as the 
primary monocytes. Human endothelial cells (HUVECs) were isolated from umbilical 
veins and cultured as previously described38. One hour prior to adding eRNA to 
HUVECs, they were washed twice with HBSS and cultured in serum-free M199 medium. 
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In select studies, thrombin (0.1U/mL) was added to cells for the time indicated. RNAse I 





5S-Spinach. The pAV-5S-Spinach construct was a gift from the Jaffrey lab 
at Cornell39. It was subcloned into the pCS2
+
 vector (Addgene, Cambridge, MA) 
downstream of the SP6 promoter using BamHI to cut the vector and BamHI/NotI to 
remove the insert from its original vector.  
 pCS2
+
tRFP. The tRFP construct was synthesized by PCR amplification of tRFP 
from pRFP-C-RS (Origene, Rockville, MD) with primers containing the restriction sites 
for ligating into pCS2
+
: forward primer with BglII restriction enzyme (RE) site (5ʹ -
GATCAGAGATCTCACCATGAGCGAGCTGATCAAGG-3ʹ) and reverse primer with 
BamHI RE site (5ʹ -GATCAGGGATCCCTCTTCATCTGTGCCCCAG-3ʹ). The PCR 
product was digested with the enzymes indicated and ligated into the pCS2
+
 vector 
downstream of the SP6 promoter. 
 IRES-NFLAG-tRFP. pT7CFE1-NFtag vector (Thermo Scientific, Rockford, IL) 
was cut with BamHI. PCR amplification of tRFP from pRFP-C-RS (Origene, Rockville, 
MD) was done with primers containing the restriction sites for ligating into pT7CFE1-
NFtag: forward primer with BglII RE site (note: 1bp smaller than the primer noted for 
pCS2
+
tRFP construct to maintain reading frame from FLAG tag to tRFP insert) (5ʹ-
GATCAGAGATCTCACATGAGCGAGCTGATCAAGG-3ʹ) and reverse primer with 
BamHI RE site (5ʹ-GATCAGGGATCCCTCTTCATCTGTGCCCCAG-3ʹ). The PCR 
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product was digested with the enzymes indicated and ligated into the pT7CFE1-NFtag 
vector downstream of the T7 promoter.  
 tRFP-Spinach. The pCS2
+
tRFP construct was cut with XhoI and XbaI and the 
pAV-5S-Spinach construct with SalI and XbaI. The fragment from the pAV-5S-Spinach 
construct was then ligated into the pCS2
+
tRFP vector to create a construct with Spinach 
downstream of the tRFP ORF.  




GMCSF. GM-CSF (NM_000758) was PCR amplified from primary human 
monocyte cDNA using primers with a BamHI site on the forward primer (5ʹ-
TGTGTTGGATCCAGGATGTGGCTGCAGAGCCTGC-3ʹ) and a XhoI site on the 
reverse primer (5ʹ-TGTGTGCTCGAGTCACTCCTGGACTGGCTCCCAG-3ʹ). The PCR 
product was digested with the enzymes indicated and ligated into pCS2
+
 cut with the 
same enzymes.   
 All constructs were sequenced to confirm identity. In addition, constructs were 
transfected into HeLa cells using Lipofectamine 2000 (Life Technologies, Grand Island, 
NY) to confirm that the open reading frame coded for a functional protein. For RFP, cells 
were inspected visually 24h after transfection using an EVOS microscope (AMG, 
Bothell, WA) to confirm the presence of RFP. For remaining constructs, cells were 
harvested and used as positive controls in subsequent assays. For example, HeLa cell 
lysates from cells transfected with the luciferase construct were used as positive controls 




 For western blot analysis, cell lysates were prepared by centrifuging cells and 
resuspending directly in Laemmli buffer, then sonicating for 5ʹ to shear DNA and reduce 
the viscosity of the sample. Sample from approximately 2.5X10
7
 platelets was loaded in 
each lane of a 12% SDS-polyacrylamide gel and electrophoresed to resolve proteins41. 
Proteins were transferred onto a PVDF membrane and probed with the following 
antibodies: anti-RFP cat # MA5-15257 (Thermo Scientific, Rockford, IL) at a dilution of 
1:1000, anti-actin cat #691002 (MP Biomedicals, Santa Ana, CA) at a dilution of 
1:50,000, anti-FLAG cat# F3165 (Sigma-Aldrich, St Louis, MO) at a dilution of 1:5000. 
Secondary antibody was HRP-conjugated goat antimouse cat# G-21040 (Life 
Technologies, Grand Island, NY). Luminescence was generated for detection using ECL 
western blotting detection reagents (GE Healthcare, Waukesha, WI). Membranes were 
probed independently with antibody, stripped with Restore Western blot stripping buffer 
(Thermo Scientific, Rockford, IL), and reprobed with another antibody as needed. 
 For flow cytometry, 10µL of the platelet suspension (at 100,000/µL) was left 
untreated or stimulated for 15ʹ with thrombin (0.1U/mL), then stained with CD41a-PE 
and either CD62P-FITC or PAC-1-FITC (BD Biosciences, San Jose, CA). Isotype 
controls used were IgM-FITC (eBioscience, San Diego, CA) and IgG1-FITC (BD 
Biosciences, San Jose, CA). After 10ʹ incubation with antibodies, cells were fixed with 
FACS Lysing Solution (BD Biosciences, San Jose, CA) and analyzed using a FACS 
CantoII flow cytometer (BD Biosciences, San Jose, CA) and FlowJo analysis software 
(Tree Star, Ashland, OR).  
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 For luciferase detection, the Luciferase Assay System (Promega, Madison, WI) 
was used according to manufacturer instructions. Briefly, 1x10
8
 platelets were pelleted 
and resuspended in 20µL of Passive Lysis Buffer, and incubated for 15ʹ at room 
temperature. Opaque white flat-bottom 96-well plates were prepared with 50µL 
LARII/well, and 10µL of sample was added. The plate was read on a Synergy HT 
luminometer (Bio-Tek, Winooski, VT). HeLa cell lysate from cells transfected with the 
luciferase construct used for in vitro transcription (IVT) were run on the same plate as a 
positive control. 
 For the GM-CSF ELISA, a sandwich ELISA kit was purchased (R&D Systems, 




were incubated with 1µg/mL RNA for GM-CSF for 
2.5h, 5h and 18h. Where indicated, 0.05U/mL thrombin was added to the platelet 
suspension 30ʹ prior to the time when cells and supernatants were harvested. Cells were 
centrifuged at 12,000xg for 3ʹ and supernatants were transferred to a new tube. Pellets 
were resuspended in 200µL RIPA and incubated for 30ʹ on ice prior to centrifugation to 
remove insoluble material. The solubilized fraction from the cell pellet was transferred to 
a new tube and stored at -80°C. The ELISA plate was prepared as directed by the 
manufacturer, and dilutions of 1:4 and 1:40 of the cell pellet were assayed, as well as 1:2 
and 1:20 of the supernatant. 
 
Microscopy 
 Fluorescence microscopy was performed on a confocal microscope using a 
60x/1.42 NA oil objective as previously described15. FV1000 image acquisition software 
Version 5.0 (Olympus, Center Valley, PA) was used for recording images. The small 
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molecule 3,5-difluoro-4-hydroxybenzylidene imidazolinone (DFHBI) (Lucerna 
Technologies, New York, NY) was added to cells immediately prior to imaging, where 
indicated.  
 
In vitro transcription (IVT) 







GMCSF) or MegaScript T7 (IRES-NFLAG-tRFP) kits (Life 
Technologies, Grand Island, NY) according to manufacturer instructions. 5ʹ-ARCA 
capped and polyA tailed IVT RNAs were generated using mMessage mMachine ULTRA 
kits (Life Technologies, Grand Island, NY) as directed by the manufacturer. Alexa-488-
labeled RNA was synthesized using FISH Tag RNA Green kit (Life Technologies, Grand 
Island, NY) as directed by the manufacturer. All transcripts were confirmed by 
formaldehyde-agarose gel electrophoresis41 and quantitated using a Nanodrop 2000 
spectrophotometer (Thermo Scientific, Rockford, IL).  
 
RNA analysis 
 Cell pellets were lysed in Trizol, cell suspensions in Trizol LS (Life 
Technologies, Grand Island, NY) and RNA was isolated as recommended by the 
manufacturer. Glycogen was added during the isopropanol step to facilitate precipitation. 
RNA pellets were resuspended in 10µL RNAse-free water and the entire sample was 
used for cDNA synthesis. Random hexamers and SuperScript II (Life Technologies, 
Grand Island, NY) were used to synthesize cDNA. Relative transcript levels were 
determined in a SYBR-Green based real-time PCR assay on a Bio-rad iCycler iQ using 
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perfeCTa SYBR Green supermix (Quanta Biosciences, Gaithersburg, MD). All RT-PCR 
shown was performed with primers specific for the luciferase transcript (5ʹ-
GAGGTGGACATCACTTACGCTGAG-3ʹ and 5ʹ-
CCCATACTGTTGAGCAATTCACGTTC-3ʹ). Data were normalized to the 
housekeeping gene β2 microglobulin using specific primers (5ʹ-
AGATGAGTATGCCTGCCGTGT-3ʹ and 5ʹ-AGCTACCTGTGGAGCAACCTG-3ʹ) 
 
Statistical analysis 
 Error bars represent the mean +/- the standard error of the mean.  
 
Results 
Platelets take up exogenous RNA 
 Our interest in platelet biology led us to test whether platelets take up an IVT 
eRNA delivered in their culture medium. Initial studies were performed using an RNA 
aptamer mimic of green fluorescent protein tagged 5S-ribosomal RNA subunit (5S-
Spinach) IVT using our pCS2
+
5S-Spinach construct39.  We reasoned that this transcript 
would not be subject to translation and would allow us to visualize any RNA uptake by 
the platelets. Confocal microscopy of unstimulated platelets incubated with this eRNA 
and DFHBI showed evidence of eRNA within the platelets (Fig. 2.1a). Cells incubated 
with DFHBI alone, a small molecule that requires the RNA aptamer to stabilize it to emit 
fluorescence, showed a very small amount of background fluorescence, but were clearly 
distinguished from the cells where the RNA aptamer was present (Fig. 2.1b). This 
important control ruled out the possibility of DFHBI being stabilized by an endogenous  
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Figure 2.1: Exogenous RNA tagged with a fluorescent aptamer is taken up by 
platelets. Platelets were incubated in the presence (a, c) or absence (b) of 1µg/mL 5S-
Spinach RNA overnight and placed on immobilized fibrinogen for live imaging. 
DFHBI was added immediately prior to imaging (a, b). Corresponding transmission 
images are shown in the top row. 
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RNA within the platelets resulting in fluorescence in the absence of eRNA uptake. 
Platelets incubated with eRNA but without DFHBI also failed to show fluorescence, 
although debris present outside of the focal plane resulted in spurious autofluorescence 
(Fig 2.1c).  
 As each RNA molecule is only tagged with one fluorophore-binding aptamer, we 
sought a more robust way to label the RNA for visualization. In addition, we wanted to 
determine whether eRNA uptake was restricted by size. We generated mRNA for 
luciferase by IVT, a transcript which is twice as long as the 5S-Spinach transcript, and 
labeled it with Alexa-488. We determined that each transcript was labeled with 6-7 
fluorophores. After incubation with this Alexa-488-eRNA in suspension, platelets were 
allowed to adhere to fibrinogen-coated coverslips in the presence of thrombin prior to 
fixation and visualization by confocal microscopy. In these spread platelets, the eRNA 
was clearly visualized as bright punctae within the granulomere of the platelet (Fig. 2.2a). 
No green fluorescence was seen within spread platelets incubated with an eRNA which 
was not labeled with Alexa-488 (Fig. 2.2b). Platelet granules are heterogeneous, and 
subpopulations of these granules can be identified using granule-specific markers42. 
Future studies will seek to identify whether these eRNAs are located within a specific 
granule compartment to better understand what role they may be playing there. 
 
eRNA uptake by platelets is time- and concentration-dependent 
 Uptake of eRNA by platelets has not been previously reported, so we next sought 
to characterize this uptake. Initial work focused on using the 5S-Spinach IVT RNA for 
passive uptake, followed by RT-PCR. Despite extensive testing with 7 different primer  
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Figure 2.2: Exogenous RNA labeled with Alexa-488 is visible within the granulomere of 
spread platelets. Platelets were incubated for 2h with 100ng/mL eRNA labeled (a) with 
and (b) without Alexa-488 after IVT. Samples were stimulated with 0.1U/mL thrombin 
and plated onto fibrinogen-coated coverslips and allowed to spread for 45' at 37°C prior 
to fixation and imaging. Green represents labeled RNA. The red stain represents actin. 
 32 
pairs, however, nonspecific amplification was a consistent problem. Therefore, we used 
the IVT RNA for luciferase, as we knew it was able to be taken up by platelets (Fig. 2.2).  
Primers for luciferase were optimized and used to determine the kinetics of eRNA uptake 
in platelets. This luciferase eRNA rapidly associated with isolated platelets, with a 
maximum amount detected at 15ʹ and decreased association over time (Fig. 2.3, bars). 
Interestingly, RNA was still detectable in these samples after overnight incubation. To 
determine whether the eRNA we were detecting was associated with the membrane or 
internalized within the platelets, we added RNase I prior to harvest of the samples. RNase 
I is a ribonuclease that will robustly cleave any single-stranded RNA not protected from 
degradation by a membrane barrier43. RNase treatment of our samples at 15ʹ showed that 
little of the eRNA associated with the platelet membrane had been internalized at this 
early timepoint, as it is not protected from degradation by RNase I (Fig. 2.3, line). 
Internalization of eRNA reached a peak at 2h and gradually declined over an 18h period. 
Of note, we found that the amount of RNase-protected eRNA after overnight incubation 
is identical to the amount of total RNA associated with the platelets. This suggests that 
eRNA not internalized by platelets is completely degraded after an overnight incubation.  
 To determine whether the uptake of eRNA was concentration-dependent, we 
repeated the experiments with varied concentrations of eRNA. When 10-fold less eRNA 
was added to the platelets, we see similar kinetics for the eRNA protection, with a peak at 
2h and a decline overnight (Fig. 2.4a). However, the amount of eRNA that was protected 
at this peak is 4-fold less than we saw with the initial experiments (0.12 vs 0.45), 
suggesting that uptake is concentration-dependent and not saturated at lower 
























































































Figure 2.3: Time course of RNA uptake by platelets. Platelets were incubated with 
100ng/mL eRNA for the times indicated (O/N- overnight). To harvest total membrane-
associated eRNA, cells were centrifuged, washed and resuspended in Trizol prior to 
total RNA isolation and RT-PCR with primers specific for the eRNA cDNA (bars). To 
harvest platelet-associated RNase-protected eRNA, samples were incubated with 




Figure 2.4: Concentration response of RNA uptake by platelets. Platelets were 
incubated with (a) 10ng/mL or (b) 1000ng/mL eRNA for the times indicated. 
Total membrane-associated eRNA and RNase-protected eRNA were assayed as 
described in Fig. 2.3. 
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kinetics remain the same, but the protected fraction at 2h is only about 2-fold higher than 
with the intermediate dose (0.95 vs 0.45). Taken together, these data suggest that uptake 
of eRNA is a regulated process that is saturable. 
 
eRNA uptake is unique to platelets 
 Given the robust uptake of eRNA by platelets, we wanted to determine whether 
this was a property unique to platelets. Primary human monocytes and THP-1 cells, an 
immortalized monocytic cell line, were each incubated with eRNA for 2h or overnight 
and the amount of RNase-protected eRNA was determined. Surprisingly, almost no 
eRNA was protected by either monocytes or THP-1 cells under the conditions tested (Fig. 
2.5a). When eRNA was added to a coculture of platelets and monocytes, there was a 
small amount of protected eRNA detected, but not nearly as much as when platelets and 
eRNA were incubated without monocytes. Since we saw rapid association of eRNA with 
platelet membranes in our previous experiment (Fig. 2.3, bars), we also tested whether 
platelets incubated with eRNA for 15ʹ prior to addition of monocytes led to significant 
protection of eRNA after 2h or overnight coculture. As seen in the figure, preincubation 
led to a slight increase in the amount of protected RNA as compared to when platelets 
and monocytes were immediately coincubated, but was not able to restore eRNA 
protection to the level of platelets alone. 
 The ability of platelets to internalize eRNA, but not monocytes or THP-1 cells, 
led us to interrogate the fate of eRNA in monocytes and THP-1 cells more rigorously. 
Specifically, we determined if eRNA simply fails to be internalized by these cells or if it 
is actively degraded. Here, we isolated total RNA from the cell suspensions incubated  
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Figure 2.5: Exogenous RNA uptake is unique to platelets. Platelets, monocytes and THP-
1 cells were incubated with 100ng/mL eRNA for the indicated times. For a) 100U/mL 
RNaseI was added 15' prior to harvest and cells were incubated at 37°C. Trizol LS was 
added to samples (3:1 v/v), total RNase-protected RNA was isolated and RT-PCR for 
eRNA was performed. In b) Trizol LS was added to samples (3:1 v/v) without RNase 
treatment, total RNA was isolated and RT-PCR for eRNA was performed. Values were 
normalized to β2 microglobulin (B2M), which was expressed at similar levels in all cells 
under the conditions of this assay. Panel c) indicates the cycle threshold value for eRNA 
incubated under identical culture conditions to cells, demonstrating the stability of the 
IVT RNA during the course of our assay.  
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with eRNA without RNase-I treatment. The values generated from this experiment are 
indicative of total eRNA in the sample (extracellular, membrane-associated and 
intracellular). At 2h, total eRNA in the platelet only sample was 400-fold higher than in 
any of the other conditions tested (Fig. 2.5b). The dramatic reduction in the total eRNA in 
the monocyte and THP-1 cultures suggests that these cells actively and rapidly degrade 
eRNA. Upon overnight incubation with eRNA, the amount of eRNA in the monocyte and 
THP-1 samples was nearly undetectable, while there was still a significant amount of 
eRNA in the platelet only cultures. The decrease in total eRNA between 2h and 18h in 
the platelet cultures suggests platelets degrade eRNA, albeit less efficiently and more 
slowly than monocytes or THP-1 cells. Importantly, incubating IVT RNA in media 
overnight under the same conditions as cell culture resulted in no change in cycle 
threshold by RT-PCR (Fig. 2.5c), indicating that the decreases in signal in this assay are 
due to an active degradation process and not the inherent lability of RNA. Additional 
experiments demonstrated that media in which monocytes have been cultured for 2h and 
then removed is sufficient to induce RNA degradation in this assay. Platelet-conditioned 
media leads to eRNA degradation to a much lesser extent (data not shown). This result 
suggests that monocytes and THP-1 cells constitutively secrete a factor capable of 
degrading eRNA in the media rather than degrading eRNA through an internalization-
dependent process. 
 
Exposure to eRNA does not alter platelet activation 
 Activated platelets express P-selectin on their surface44, as well as the activated 
form of the integrin αIIbβ3, which is measured using the activated integrin-specific 
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antibody PAC-145. To determine whether exposure to eRNA leads to platelet activation, 
we performed flow cytometry. After 2h of incubation in the presence of two different 
concentrations of eRNA, we saw no increase in the expression of P-selectin on the 
surface (Fig. 2.6c,e) compared to untreated platelets (Fig. 2.6a). Similar results were 
obtained when using PAC-1 binding to determine integrin αIIbβ3 activation in these 
samples (Fig. 2.7). These results indicate that eRNA does not cause platelet activation. 
 To determine whether exposure to eRNA impacts the ability of platelets to 
respond to traditional agonists, we preincubated platelets for 2h with eRNA and then 
stimulated them with thrombin and measured P-selectin surface expression and PAC-1 
binding. Platelets exposed to either low (Fig. 2.6d) or high (Fig. 2.6f) concentrations of 
eRNA expressed similar levels of P-selectin on their surface after thrombin stimulation as 
thrombin-stimulated platelets not exposed to eRNA (Fig. 2.6b). Using PAC-1 binding to 
determine integrin αIIbβ3 activation in these samples yielded similar results (Fig. 2.7). 
Taken together, these data indicate that eRNA alone does not cause platelet activation 
and platelets exposed to eRNA are able to activate normally in response to thrombin. 
  
eRNA is not translated 
 To determine whether eRNA taken up by platelets is translated, several constructs 
for IVT of red fluorescent protein (RFP) were designed. The standard transcript for tRFP 
was synthesized without and with a 5ʹ cap, a modification which is known to improve 
translation46. An additional construct with the Spinach aptamer downstream of tRFP was 
created with the intention of tracking RNA uptake and translation in live cells39. Finally, 
tRFP was cloned into a construct containing an IRES-FLAG tag, which has been shown  
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  Figure 2.6: Platelets exposed to eRNA translocate P-selectin to their 
membrane in response to thrombin normally. Platelets were incubated in the 
absence (a,b) or presence of 100 ng/mL (c,d) or 1000ng/mL (e,f) eRNA for 
2h. After incubation, platelets were stimulated with 0.1U/mL thrombin 
(b,d,f) for 15ʹ prior to staining with antibodies for P-selectin and CD41a and 
analyzed by flow cytometry. Figure is representative of three experiments.  
 40 
          
  
Figure 2.7: Platelets exposed to eRNA bind PAC-1 in response to 
thrombin normally. Platelets were incubated in the absence (a,b) or 
presence of 100 ng/mL (c,d) or 1000ng/mL (e,f) eRNA for 2h. After 
incubation, platelets were stimulated with 0.1U/mL thrombin (b,d,f) for 
15ʹ prior to staining with antibodies for the active integrin αIIbβ3 (PAC-
1) and CD41a and analyzed by flow cytometry. Figure is representative 
of three experiments.  
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to promote cap-independent translation47. Western blot analysis of platelet lysates 
incubated with equal amounts of each of these IVT eRNAs showed a multitude of bands 
cross-reacting with the anti-RFP antibody, but a band induced over time at approximately 
the correct size for tRFP (Fig. 2.8). Using this same antibody for immunocytochemistry 
(ICC), we detected a signal in platelets incubated with the eRNA overnight (Fig. 2.9b) 
that was not present in baseline platelets (Fig. 2.9a). To confirm these results, the 
experiment was repeated using untreated platelets and platelets incubated with an IVT 
RNA coding for 5S-Spinach, which should not cross-react with the RFP antibody. 
Western blot analysis of these lysates showed a band induced at the size expected for 
RFP under all of the conditions tested (Fig. 2.10). This suggests that the immunoreactive 
band detected by the anti-RFP antibody is not RFP. An additional western blot was 
prepared with lysates incubated with the FLAG-tagged RFP IVT RNA and probed with 
an anti-FLAG antibody. No signal was seen on this blot at any timepoint, further 
confirming that the eRNA taken up by the platelets was not being translated under these 
conditions (data not shown). Finally, the immunocytochemistry was repeated using 
platelets incubated for 18h without eRNA. This experiment showed an equivalent amount 
of localized signal when stained with the anti-RFP antibody between platelets treated 
with or without eRNA, providing further evidence that our antibody cross-reacts with a 
nonspecific band which is induced in cultured platelets (data not shown). 
 We were interested in testing whether platelets could translate a small, 
biologically relevant protein product from eRNA. Transcriptome and proteomics analysis 
of platelets have shown that platelets do not express appreciable amounts of GM-CSF48,49. 















Figure 2.8: Platelets appear to express protein from eRNA by western blot analysis. 
Platelets were incubated with 1µg/mL eRNA synthesized from the constructs 
indicated. Samples were lysed and run on SDS-PAGE, transferred to PVDF and 
probed with antibodies for RFP and actin. The arrow indicates the induced band at 










Figure 2.9: Platelets appear to express protein from eRNA by immunocytochemistry. 
Platelets were incubated with 1µg/mL eRNA coding for tRFP, fixed in suspension and 
cytospun onto coverslips and stained with anti-RFP. Panel a) platelets at baseline. Panel 
























                  
Figure 2.10: Induced band in platelets is not RFP. Platelets were incubated without 
eRNA, with eRNA which does not code for RFP and with the RFP eRNA. The time-
induced band is visible under all conditions, confirming that the RFP antibody is cross-
reacting with a nonspecific band induced in platelets under these conditions.  
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associated with sepsis50. We reasoned that this would be an attractive candidate for 
platelets to synthesize in a clinical setting. A construct was prepared and GM-CSF 
mRNA was IVT and incubated with platelets in the presence or absence of thrombin. 
Both supernatants and cell pellets were assayed for GM-CSF protein at 2.5h, 5h and 24h 
by ELISA. No protein was detected at any of the timepoints under any of the conditions 
tested (data not shown).  
Due to the difficulty with the RFP antibody and the low sensitivity of antibody-
based assays, we used a luciferase assay as a more sensitive and specific method for 
detecting protein expression in platelets from eRNA. The coding sequence for luciferase 
was IVT with a 5ʹ cap and a polyA tail and incubated in the presence of platelets. 
Samples taken at 2h, 4h, 8h and 18h all failed to show any luciferase activity. Despite our 
evidence that platelets take up eRNA, we have not been able to detect translation of 
eRNA in platelets under any conditions tested.  
Our lab has previously demonstrated the ability of activated platelets to induce 
synthesis of chemokines by monocytes through a receptor-mediated mechanism21. In 
addition, recent work by another lab suggests that platelet-like particles, a particle created 
in a cell culture system, are capable of transferring RNA to other cells51. We wanted to 
determine whether platelets take up eRNA to protect it from extracellular ribonucleases 
and then transfer it to monocytes for subsequent translation. Platelets were incubated with 
eRNA coding for luciferase for 2h, the timepoint at which we saw maximal eRNA uptake 
in our earlier experiments (Fig. 2.3). After preincubation with eRNA, monocytes and 
thrombin were added to the platelets and samples were taken at 2h, 4h, 8h and 18h to 
assay for luciferase activity. There was no detectable luciferase activity under any of the 
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conditions tested, suggesting that this eRNA is not transferred to monocytes from 
platelets for translation.  
  
Discussion 
 The release of RNA from cultured human cells under basal conditions was first 
described in 197852. Since then, the presence of eRNA in body fluids including plasma, 
serum and urine has been detected in both healthy and diseased individuals53,54. The 
majority of this extracellular RNA is likely packaged in membrane-bound microparticles 
(MP) that are protected from plasma ribonucleases. Consistent with this, filtration or 
ultracentrifugation significantly decreases the level of detectable RNA in plasma55. RNA 
packaged in MP is enriched for certain RNAs relative to the RNA profiles in the cells 
from which they originate, and is capable of being translated in target cells56,57. Activated 
platelets are known to be an important source of MP, but multiple other cell types 
including monocytes, endothelial cells and tumor cells have been shown to release MP as 
well58,59. While MP appear to represent an important means of intercellular 
communication, the mechanisms by which cargo is packaged into and vesicles are 
released from cells remain to be characterized and hamper our understanding of their 
physiological relevance60. 
 In addition to uptake of RNA packaged within MP, naked RNA has been shown 
to be taken up by cells as well. Injection of RNA coding for luciferase into mouse 
skeletal muscle and intradermally results in expression of luciferase within fibroblasts, 
dendritic cells and muscle cells which is time and concentration-dependent61-63. RNA 
molecules can serve as transient carriers of information without the risks of genomic 
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integration and insertional mutagenesis carried by DNA vectors64. Vaccination with 
mRNA in mice has been shown to result in specific immunologic responses against the 
antigen which the RNA codes for, and the possibility of this technology to generate host 
antitumor responses is promising65,66. Despite the work that has been done to understand 
exogenous RNA uptake in tissues and in cell culture systems, until the observations 
presented here nothing was known about platelet responses to eRNA.  
 Here, we describe for the first time the ability of quiescent platelets to rapidly take 
up and protect eRNA from RNase in culture. Exposure to eRNA does not lead to surface 
expression of P-selectin, binding of PAC-1 or alter the ability of platelets to respond to 
thrombin, suggesting eRNA does not result in direct platelet activation. We observed 
uptake of eRNA of varying sizes, and uptake was determined to be time and 
concentration-dependent. In nucleated cells, eRNA uptake has been shown to occur via 
scavenger receptors, as treatment with ligands for these receptors competes with eRNA 
for internalization63. In addition, double stranded RNA uptake in macrophages has been 
shown to occur through integrin receptors67.We have not yet tested whether scavenger 
receptors or integrins are responsible for eRNA uptake by platelets, but platelets are 
known to express CD36 and SR-BI as well as integrins, and this possibility will be 
explored in future studies68. 
 Interestingly, other cells we tested not only failed to take up eRNA, but released 
factors into the culture media that led to rapid RNA degradation. This is in contrast to 
reports from other groups demonstrating that passive pulsing of mRNA into a variety of 
cell types leads to detectable translation of the mRNA after 24h62,63. As these other reports 
used 10-fold more eRNA (or more) than we did, it is possible that our assay was below 
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the limit of detection. It is striking, however, that eRNA uptake by platelets is so robust 
compared to other cells (Fig. 2.5).  
 Our lab has previously demonstrated the ability of activated platelets to translate 
endogenous mRNA in response to extracellular cues69, leading us to test the hypothesis 
that eRNAs would be translated within platelets. Using immunocytochemistry, western 
blotting, ELISA and luciferase assays with the corresponding eRNAs, we were unable to 
detect translation at any timepoint, even in the presence of thrombin. Our microscopy 
studies showed localization of eRNA within the granulomere of spread platelets, and 
more work needs to be done to determine if the eRNA is found within a lysosome, 
granule or other compartment. It is possible that eRNA taken up by platelets is 
sequestered within a compartment that is inaccessible to translation machinery. One 
group has reported localization of eRNA within lysosomes of nucleated cells, with 
concomitant degradation of the bulk of the eRNA63. In addition to localization studies by 
microscopy, we are undertaking radiolabeled eRNA experiments to determine whether 
the eRNA within platelets remains intact or represents partially degraded nucleic acids 
that cannot be translated.  
 Recently, transfer of platelets from TLR2
+/+
 mice into TLR2
-/-
 mice was 
demonstrated to lead to detectable levels of TLR2 RNA within the peripheral blood 
mononuclear cells of recipient mice51. This in vivo experiment was used to confirm in 
vitro experiments done by the same lab showing RNA transfer from cultured platelet-like 
particles to THP-1 cells, and subsequent protein expression. While we were not able to 
detect any luciferase expression in primary human monocytes or THP-1 cells cultured 
with platelets containing eRNA for luciferase, it is possible that this is due to a technical 
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limitation of our assay, and further optimization may lead to detectable RNA transfer. We 
will continue to study the interactions between platelets and leukocytes with the aim of 
better understanding how the interaction between these cells affects their function. 
 Translation is not the only means by which eRNA uptake by platelets may exert a 
physiologic effect. Extracellular RNA has been reported to serve as a scaffold for 
coagulation factors, with RNase treatment (but not DNase treatment) delaying occlusive 
thrombus formation in mouse models of vascular injury37. As platelets play an active role 
in thrombus formation, they are poised to interact with eRNA and possibly downregulate 
the contact phase of coagulation, allowing for previously unrecognized and additional 
layers of control over hemostasis. To further our understanding of how platelet uptake of 
eRNA may alter coagulation responses, additional work characterizing the mechanism by 
which eRNA is taken up by platelets will be needed.  
 Far from being an inert molecule, extracellular RNA is gaining increased 
appreciation as not only a marker of disease but also an important player in physiological 
responses. The work presented here provides the first evidence that platelets take up 
eRNA and characterizes our incomplete understanding of the outcome of this uptake on 
platelet function.  
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A GENETIC SCREEN TO IDENTIFY NOVEL FACTORS FOR NEUTROPHIL 
EXTRACELLULAR TRAP FORMATION 
 
Abstract 
 The ability of neutrophils to release DNA creating extracellular traps (NETs) has 
been shown to play an important role in innate immune defense against pathogens as 
diverse as bacteria, fungi and protozoan parasites.  Since the first report of this 
antimicrobial activity nearly a decade ago, much has been learned about this previously 
unrecognized process. Using primary human neutrophils as well as animal models, a 
variety of signals including direct interactions with platelets, factors released by platelets 
and small molecules have been shown to contribute to NET formation in addition to the 
pathogens mentioned above. Naturally occurring genetic models, such as patients with 
chronic granulomatous disease, have also established the requirement of nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidase for this process. Despite rapid 
progress made in understanding the mechanism by which NETs form, known as 
NETosis, much remains to be learned. Here, we describe a genetic screen we developed 
to identify novel factors required for NET formation. Using the nearly haploid human cell 
line, KBM-7, we determined conditions that were permissive for NET formation in 
culture. Retrovirus was generated to deliver gene-trap constructs by transduction for 
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mutagenesis of a pool of KBM-7 cells and a plate-based assay was created to allow us to 
screen for clones with disruption of genes required for NETosis. Unexpectedly, 
integration of the gene trap construct failed to result in detectable expression of the 
marker gene (either GFP by flow cytometry or resistance to puromycin), despite 
detectable integration by PCR. This limitation made execution of the screen unfeasible as 
designed, as initial selection for successful mutagenesis is necessary to bring the costs of 
the screen (in time and reagents) within a manageable level. Despite this setback, future 
developments in bioinformatics may allow the foundational work described here to be 
utilized in a pooled screen to identify new genes required for NET formation. 
 
Introduction 
 Neutrophils are the most abundant white blood cells in humans, accounting for 
between 50 and 70% of the leukocytes in peripheral blood. Their importance as first-
responders in innate immune defense against pathogens is made apparent by an increased 
susceptibility to bacterial infections in neutropenic patients. The observation that 
neutrophils are found associated with bacteria in lesions initially led to the false 
conclusion that neutrophils promoted the growth of bacteria within the host1. Using a 
thorough experimental and evolutionary approach, Metchnikoff clearly demonstrated in 
the early 20
th
 century that neutrophils engulf pathogens to affect phagocytic killing of 
invaders2. In the subsequent century, the mechanisms by which neutrophils provide 
innate immune defense were elucidated. Activated neutrophils were demonstrated to 
either phagocytize microorganisms, exposing them to hydrolytic enzymes and 
antimicrobial proteins as well as reactive oxygen species within the phagosome, or 
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release toxic granules into the extracellular space3. In either case, the goal is to kill the 
invading organism while causing minimal damage to the host.  In 2004, Brinkmann 
reported a third and previously unrecognized mechanism by which neutrophils could 
protect against pathogens: neutrophil extracellular traps (NETs)4.  
 NETs consist of decondensed chromatin decorated with proteins from primary, 
secondary and tertiary neutrophil granules4. NET formation can be distinguished from 
apoptosis by the absence of DNA fragmentation, phosphatidylserine exposure or caspase 
activation5. Rather, cells undergoing NETosis lose their nuclear membrane integrity, 
whereupon decondensed chromatin mixes with the contents of cytoplasmic granules prior 
to cell death and release of the NET5. This process has been described in humans, mouse 
and fish as well as several other species6-10. In addition to being conserved across multiple 
organisms, NETs can be induced by a multitude of signals. Bacteria known to induce 
NETs include Staphylococcus aureus, Haemophilus influenza, Mycobacterium 
tuberculosis and Escherichia coli11-14. Fungi such as Candida albicans and Aspergillus 
nidulans, in both the yeast and hyphal forms, can be killed by NETs15,16. Protozoan 
parasites including Leishmania amazonensis, Toxoplasma gondii and Plasmodium 
falciparum have also been reported to induce and be killed by NETs17-19. Isolated 
components of microbial cell walls such as lipopolysaccharide (LPS) and fMLP as well 
as inflammatory cytokines, activators of protein kinase C and even interactions with 
platelets and antimicrobial β-defensins released from platelets have all been shown to 
induce NETosis4,20-22.  
 Given the central role of neutrophils in defense against pathogens, the diversity of 
signals which can lead to NET formation is not surprising. However, it is clear that tight 
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regulation of such a process is also important to prevent harm to the host. The delicate 
balance between benefit and harm is illustrated by the association of NETs with both 
acute and chronic pathologies. Markers of NET formation have been found in the blood 
of patients with transfusion-related acute lung injury (TRALI) and directly observed in 
the lungs in mouse models of TRALI23,24.  Administration of DNase I, either 
intravenously or by inhalation, improved outcomes in these models. NETs have been 
shown to damage activated endothelium and contribute to end organ damage in mouse 
models of sepsis22. NETs also provide a scaffold for platelet and red blood cell deposition 
within the vasculature, contributing to thrombus formation, which can be prevented with 
the administration of DNase I25,26. In the autoimmune disease systemic lupus 
erythematosus, the serum from a subset of patients with active disease demonstrated a 
decreased ability to degrade NETs and concomitant complement deposition, suggesting a 
role for NETs in autoantibody production27. Taken together, these studies illustrate how 
important understanding the molecular mechanisms driving NET formation are for 
therapeutic purposes. 
 The initial report describing NETs demonstrated that actin polymerization was not 
required for NET formation4. Subsequent work focused on NADPH oxidase and 
generation of reactive oxygen species (ROS), a mechanism known to be critical for 
phagocytic killing by neutrophils. Treatment of neutrophils with the small molecule 
inhibitor of NADPH oxidase  diphenylene iodonium (DPI) blocks NET formation, while 
treatment with glucose oxidase to generate ROS downstream of NADPH oxidase is 
sufficient to drive NET formation, even in the presence of DPI5. Neutrophils from 
patients with chronic granulomatous disease (CGD) containing mutations in NADPH 
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oxidase fail to form NETs in response to agonist, a defect which can be reversed by 
adding glucose oxidase, providing genetic evidence that  ROS are required for NET 
formation5. However, experiments demonstrating that neonatal neutrophils have a 
developmental defect in NET formation that cannot be rescued upon addition of glucose 
oxidase indicate that ROS generation is not sufficient to execute NETosis, and additional 
signaling pathways are likely involved28. Mouse knockout models have been used to 
demonstrate a requirement for neutrophil elastase (NE) and peptidylarginine deiminase 4 
(PAD4) in chromatin decondensation; the absence of either of these genes blocks NET 
formation and increases susceptibility to infection in mouse models of pneumonia and 
necrotizing fasciitis29,30. Treatment of primary human neutrophils with rapamycin 
demonstrated that mTOR plays a role in NET formation, and shRNA knockdown of HIF-
1α in HL-60 cells differentiated into surrogate PMNs confirmed that this was dependent 
on HIF-1α31. Myeloperoxidase (MPO) has also been shown to be required for NET 
formation, as humans with mutations in the MPO gene leading to an absence of the 
protein are unable to form NETs32.  
 Both small molecule and genetic approaches have helped elucidate key pathways 
required for NET formation, but these methods have required a candidate approach. To 
gain new insights into the mechanisms of NETosis, a broader genetic screen is needed. 
Such an undertaking using animal models is unfeasible due to the time and expense 
required. A cell culture based assay is not only faster and cheaper than animal models, 
but has the potential to reach greater genome coverage due to the elimination of 
confounding effects from genes required for development. However, as human cell lines 
are generally diploid, any mutagenesis strategy randomly targeting genes would only 
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affect one of the two alleles, and only identify genes with a dominant effect on NET 
formation. The human cell line KBM-7, isolated from a patient with chronic 
myelogenous leukemia (CML) has been reported to be haploid (with the exception of 
chromosome 8) and has successfully been used to identify genes required for host 
susceptibility to pathogens using an insertional mutagenesis strategy33,34. We speculated 
that this cell line may be capable of forming NETs in vitro, as it is of myeloid origin. 
Here we describe our work demonstrating that these nearly haploid KBM-7 cells are 
capable of forming NETs, the design of our genetic screen and the barriers to executing 
the screen as designed. This foundational work can be built upon with improvements in 
bioinformatics to identify a host of factors required for NET formation and targets for 
novel therapeutics in the future. 
 
Materials and Methods 
Cell lines and culture 
 KBM-7 cells were a kind gift from the Brummelkamp lab (Netherlands Cancer 
Institute) and were cultured in IMDM supplemented with 10% FCS and antibiotics. Cells 





GP cells were obtained from the National Gene Vector Laboratory Biorepository 
(NGVB, Indianapolis, IN)35 and cultured in DMEM supplemented with 10% heat 
inactivated FBS, 2mM L-glutamine and antibiotics. Cells were maintained below 90% 
confluency. HL-60 cells were maintained according to distributor’s recommendations 
(ATCC, Manassas, VA). Unless otherwise indicated, cells were maintained in a 37°C 
humidified tissue culture incubator with 5% CO2. 
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Ploidy testing and sorting of haploid cells 
 Cell ploidy was determined using propidium iodide (PI) staining. KBM-7 cells or 
HL-60 cells (1x10
6
) were centrifuged in flow tubes, then resuspended in 500µL cold 
hypotonic DNA buffer (0.1% sodium citrate, 0.1% Triton X, 20ug/mL RNase A, 
50ug/mL propidium iodide), incubated on ice for 20ʹ and analyzed on a FACSCanto flow 
cytometer (BD Biosciences, San Jose, CA). Haploid cells were sorted based on size with 
a FACSAria sorter (BD Biosciences, San Jose, CA) at the University of Utah flow 
cytometry core facility, and confirmed by PI staining. Where indicated, cells were 
incubated in the presence of 4µg/mL aphidicolin (Acros Organics, Geel, Belgium) for 
16h prior to treatment with hypotonic DNA buffer and analysis. 
 
Plasmids 
 Gene trap constructs were a kind gift from the Brummelkamp lab (Netherlands 
Cancer Institute)34.  As constructs with LTRs frequently recombine during plasmid 
production within E. coli, losing the gene trap region while maintaining resistance to 
antibiotic selection, all plasmid preparations were confirmed by restriction enzyme digest 
prior to transfection of packaging cells for virus production. The GT-GFP plasmids 
contain the coding region for GFP within the LTRs downstream of the splice acceptor 
site, resulting in GFP expression when integration occurs within an expressed coding 
gene. The GT-Puro plasmids contain the coding region for the Pac gene within the LTRs 
downstream of the splice acceptor site, resulting in resistance to puromycin when 
integration occurs within an expressed coding gene. The VSV-G envelope plasmid for 
retrovirus was from Addgene (#14888). The CMV-GFP retrovirus positive control 
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plasmid was a kind gift from Eric Taylor in the Rutter lab (University of Utah). The 
pAdVAntage plasmid was purchased (Promega, Madision, WI).  
 
Retrovirus production 
 Phoenix-GP cells were plated the day prior to transfection onto poly-lysine coated 
tissue culture dishes at a density of 50% in antibiotic-free media. The following day, the 
media was replaced with fresh antibiotic-free media and cells were transfected at 
approximately 70-80% confluency.  Phoenix-GP cells contain genomic integrations of 
the packaging genes gag and pol, so transfection only required the envelope pseudotyping 
plasmid VSV-G, the pAdVAntage plasmid and the gene trap plasmids (either GT-GFP or 
GT-Puro) or the GFP positive control plasmid. Cells were transfected with plasmids 
using Lipofectamine 2000 (Life Technologies, Grand Island, NY) according to the 
manufacturer’s instructions and grown at 37°C. Posttransfection (4h), the media was 
replaced with fresh media containing antibiotics and the cells were incubated overnight. 
The following morning, the media was replaced again and the cells were cultured at 32°C 
for 48h. Supernatant containing virus was removed at 48h and 72h posttransfection, 
filtered through a 0.45 µm filter and stored at 4°C. After the 72h harvest, supernatant 
containing virus was pooled and ultracentrifuged for 2h at 25,000 rpm, 4°C in a SW 32 
Ti rotor (Beckman Coulter, Indianapolis, IN) to concentrate. All but 300µL of the 
supernatant was removed and the pellet was incubated overnight at 4°C, then 






 KBM-7 cells were resuspended at 0.5x10
6
/mL the day before infection to ensure 
that cells would be actively dividing for transduction. Cells were counted on the day of 
infection, centrifuged and resuspended at a concentration of 1x10
7
/mL; 10µL of cells was 
used per infection condition. Where indicated, carriers were used to promote infection. 
Protamine sulfate and polybrene (Sigma-Aldrich, St Louis, MO) were each used at a final 
concentration of 8µg/mL. Lipofectamine (Life Technologies, Grand Island, NY) was 
used at a 1:100 dilution. Concentrated virus (100µL) and carrier was added to each tube 
with cells and centrifuged at 2400xg for 90ʹ at 4°C (spinfection). After centrifugation, 
tubes were incubated for 2h at 32°C prior to the addition of 500µL fresh media and 
overnight incubation at 37°C. The following day the cells were centrifuged, resuspended 
in fresh media and subjected to a second round of spinfection. Three days after the 
second round of infection, cells were analyzed for GFP fluorescence by flow cytometry 
or puromycin resistance. Where indicated, Phoenix GP cells at 60% confluency were 




 Cells were washed, resuspended in M199 media and incubated in the presence or 
absence of the agonists indicated on coverslips for 1h at 37°C. After stimulation, cells 
were gently washed and stained with a mixture of a cell permeable (SYTO Green) and 
cell impermeable (SYTOX Orange) DNA dyes (Life Technologies, Grand Island, NY). 
Fluorescence microscopy was performed on a confocal microscope using both 20x and 
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60x oil objectives as previously described28. FV1000 image acquisition software Version 
5.0 (Olympus, Center Valley, PA) was used for recording images.  
 
PCR 
 Primers for detecting GFP gene trap integration in genomic DNA were 5ʹ-
CGGTTCACCAGGGTGTCGCC-3ʹ and 5ʹ-CGAGCTGGACGGCGACGTAA-3ʹ, which 
yield a 318bp product. Primers for detecting puromycin gene trap integration in genomic 
DNA were 5ʹ-ACCGCTCAACTCGGCCATGC-3ʹ and 5ʹ-
CCACATCGAGCGGGTCACCG-3ʹ, which yield a 178bp product. PCR was performed 
on 100ng of gDNA isolated from transduced cells or 10ng of gene trap plasmid as a 
positive control using GoTaq polymerase and reagents (Promega, Madison, WI) with 35 
cycles and a 72°C annealing temperature. 
 
Puromycin kill curve 
 Haploid KBM-7 cells (8x10
4
) were plated into each well of a 24-well tissue 
culture plate with media in the absence or presence of puromycin at varying 
concentrations (0.5 to 5µg/mL). Cells were counted every 1-2 days and graphed to 
determine the optimum puromycin dose and time to kill all nontransduced cells.  
 
Picogreen assay 
 KBM-7 cells were washed and resuspended at 2x10
6





; 200µL of cells were added to each well of a 96-well round bottom tissue culture 
plate with either no treatment or stimulation with LPS (100ng/mL), camptothecin (2µM) 
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or staurosporine (1µM) and incubated at 37°C for 30ʹ and 2h. Micrococcal nuclease 
(50U) (New England Biolabs, Ipswich, MA) was added to each well and incubated for 
10ʹ at 37°C. The plate was centrifuged and 100µL supernatant was carefully removed and 
transferred to an opaque white 96-well plate. Picogreen reagent (Invitrogen, Grand 
Island, NY) was diluted in TE according to manufacturer instructions and 100µL was 
added to each well of the assay plate and incubated in the dark for 5ʹ prior to reading on a 
Synergy HT luminometer (BioTek Instruments, Winooski, VT). Samples were run in 
triplicate and the three readings were averaged.  
 
Results 
Haploid KBM-7 cells can be isolated by FACS 
 KBM-7 cells have been selected for their ability to remain haploid in culture for 
several months, but over time ploidy can increase33. The haploid population can be 
distinguished from the remaining cells based on size. We sorted our initial culture of 
KBM-7 cells on a FACSAria cell sorter and selected the small cells based on FSC/SSC 
profiles. Using PI staining we determined that our sorting parameters were sufficient to 
enrich for haploid cells relative to the mixture of ploidy seen in the unsorted population 
(Fig. 3.1a). As haploid cells in G2 of the cell cycle are indistinguishable from diploid 
cells in G1, we treated cells with aphidicolin, a small molecule inhibitor of cell cycle that 
blocks cells in early S-phase36, to confirm that our sorted cells were haploid. Aphidicolin 
treatment of the unsorted cells resulted in a dramatic reduction in the third peak, 
corresponding to a block preventing the diploid cells in the population from transitioning 










Figure 3.1: FACS sorting of KBM-7 cells enriches for haploid population. Untreated 
KBM-7 cells (a) or KBM-7 cells pretreated with aphidicolin (b) were stained with 






loss of the second peak, confirming that this population is indeed haploid (Fig. 3.1b).  To 
ensure that subsequent experiments were performed on an enriched haploid population, 
these sorted cells were expanded and frozen in liquid nitrogen. Cells maintained in 
culture were discarded after 2-3 months to avoid potential problems with unstable ploidy. 
 
KBM-7 cells form NETs 
 Our genetic screen to identify factors required for NET formation relies on the 
ability of haploid KBM-7 cells to form NETs.   While primary neutrophils from several 
species have been shown to form NETs, as well as the promyelocytic leukemia cell line 
HL-60 6-10,37, other immortalized cell lines capable of forming NETs have not been 
reported in the literature. We tested a panel of agonists shown to induce NETosis in 
neutrophils on KBM-7 cells and saw that both PMA (Fig. 3.2b) and LPS (Fig. 3.2c) 
resulted in NET formation, as demonstrated by microscopy. Treatment with DNase 
resulted in rapid (within 15ʹ) loss of extracellular DNA (Fig. 3.2d). Note that in a 
population of cells, only a subset form NETs upon stimulation. This is consistent with 
what has previously been observed in primary neutrophils, with approximately 30% of 
neutrophils showing extracellular DNA upon stimulation5. Whether this represents a 
heterogeneous population of cells or paracrine feedback preventing excessive activation 
within the pool of cells has yet to be determined. In addition, we detected expression of 
the neutrophil markers MPO and NE by western blotting, suggesting that these cells are 
























Figure 3.2: KBM-7 cells make NETs. KBM-7 cells were incubated in the absence (a) or 
presence (b) of 20nM PMA for 1h, washed, and stained with cell permeable (green) and 
cell impermeable (red) DNA dyes prior to imaging using confocal microscopy (60x 
magnification). KBM-7 cells treated with 100ng/mL LPS were stained with DNA dyes 
and imaged (c). The sample shown in panel (c) was treated with 50U of micrococcal 
nuclease for 15ʹ, and then imaged again (20x magnification)(d). (e,f) Magnified regions 
of (c,d) to better show NET that disappears after nuclease treatment. Arrows indicate 

























KBM-7 cell NET formation can be quantitated with a plate-based assay 
 Microscopy-based evaluation of NET formation is useful for qualitative low 
throughput purposes, but we needed a more quantitative high throughput assay for our 
genetic screen. One method that has been previously reported is the quantitation of 
extracellular DNA using Picogreen reagent, which specifically binds dsDNA5. This 
technique uses a fluorescence microplate reader to analyze up to 96 wells simultaneously. 
Using this method, we saw a 2-fold increase in dsDNA when KBM-7 cells were treated 
with LPS for 30ʹ, and a similar increase at 2h (Fig. 3.3). Importantly, when cells were 
treated with camptothecin or staurosporine to induce apoptosis, there was no increase in 
dsDNA detected over the untreated samples at these time points. This is consistent with 
the observation that release of DNA from apoptotic cells occurs sometime between 6 and 
24h after initiation38, and reassured us that using the Picogreen plate assay at early 
timepoints would allow us to effectively distinguish clones which are unable to undergo 
NETosis from apoptotic cells.  
 
Generation of retrovirus and transduction 
 Production of high titer retrovirus is essential to efficiently mutagenize the 
genome of our target cells. We transfected the packaging cell line Phoenix GP, which is a 
293T cell line containing a genomic integration of the retroviral gag-pol35, with a 
construct for the VSV-G envelope protein and our gene trap constructs. Using the same 
reagents, we generated a positive control virus, which replaced our gene trap constructs 
with one containing a GFP marker downstream of a CMV promoter. While our gene trap 










Figure 3.3: Extracellular DNA quantitation by Picogreen plate assay. KBM-7 cells were 
incubated in the absence of agonist or with LPS (100ng/mL), camptotchecin (2µM) or 
staurosporine (1µM) for 30ʹ or 2h. Extracellular DNA was digested with micrococcal 
nuclease and quantitated using Picogreen reagent. Absolute values varied between 




promoterless and rely on integration into an actively transcribed gene to be expressed. 
The CMV-GFP construct produces constitutive expression of GFP and allowed us to 
optimize general transfection efficiency in the system using a fluorescence microscope 
during production. Supernatant containing virus was collected at 48 and 72h post-
transfection and concentrated via ultracentrifugation as previously described34. 
 Concentrated virus was used to infect both Phoenix GP cells, which are 
permissive to retrovirus infection, and our haploid KBM-7 cells according to detailed 
protocols from the Brummelkamp lab (personal communication), who have successfully 
mutagenized these cells previously. Cells transduced with the positive control virus or the 
GT-GFP virus were assayed 4 days postinfection by flow cytometry. Cells transduced 
with the GT-Puro virus were assayed 4 days postinfection by treating with 5µg/mL 
puromycin, and determining cell count relative to nontransduced cells on day 1 and day 
4.  This concentration of puromycin was used because it was determined to kill 100% of 
KBM-7 cells lacking the puromycin resistance gene within 4 days (Fig. 3.4). 
Unfortunately, puromycin treatment of cells transduced with GT-Puro virus showed no 
survival advantage at day 4 compared to untreated cells (data not shown). This could be 
due to poor transduction efficiency or integration into poorly expressed regions of the 
genome, leaving even successfully transduced cells susceptible to puromycin. As GT-
GFP virus can be assayed more rapidly and the CMV-GFP virus serves as a good positive 












Figure 3.4: Puromycin kill curve of KBM-7 cells. KBM-7 cells were seeded into media 
containing the indicated concentrations of puromycin and counted daily. Inset: Untreated 
KBM-7 cells cultured under identical conditions were counted daily to assess normal 




Transduction efficiency of KBM-7 cells is low 
Using the concentrated GT-GFP and CMV-GFP retrovirus, we tested a multitude 
of conditions to optimize infection of KBM-7 cells. Carrier agents such as protamine 
sulfate and polybrene are commonly used during retroviral transduction to promote 
infection, but we were unable to detect GFP expression by flow cytometry in KBM-7 
cells infected with either the GT-GFP or CMV-GFP retroviruses using these reagents 
(data not shown). It has been reported that infection in media at pH 7.7 can increase 
transduction efficiency as much as 2-fold in NIH-3T3 cells39, but we saw no change in 
GFP expression when our KBM-7 cells were transduced at pH 7.7.  In addition to 
spinfection34, we also used a transwell system to promote contact between virus and 
KBM-7 cells40, but this resulted in undetectable GFP expression in our transduced cells. 
Despite our efforts, we were unable to detect GFP expression in our KBM-7 cells under 
any conditions with either the CMV-GFP virus or the GT-GFP virus.  
To determine whether the KBM-7 cells were particularly resistant to infection or 
if there was a problem with our virus production, we tested our CMV-GFP and GT-GFP 
virus preparations for their ability to infect the Phoenix packaging cell line. Using either 
protamine sulfate or polybrene to infect Phoenix cells, we were able to achieve 
approximately 50% transduction efficiency with the CMV-GFP virus (Fig. 3.5a, b). 
However, the GT-GFP virus showed less than 1% GFP positive cells using the same 
conditions (Fig. 3.5c, d). These results suggested to us that we were capable of producing 
competent virus, as the CMV-GFP virus was able to efficiently infect these cells, but that 
GFP expression from the GT-GFP was undetectable. This may be because viral 






Figure 3.5: Flow cytometry detects GFP expression in transduced Phoenix cells. Phoenix 
cells were transduced with positive control CMV-GFP virus (a,b) or GT-GFP virus (c,d) 
in the presence of protamine sulfate (a,c) or polybrene (b,d) and assayed for GFP 




result in GFP expression below the limit of detection. This was a surprise, as the 
Brummelkamp lab has previously reported that they are able to successfully sort cells 
mutagenized with this technique using GFP expression34. Nevertheless, subsequent 
genetic screens by this lab have been reported using a pooled lethal selection approach 
rather than sorting successfully mutagenized cells41-43, and both successful infection of 
KBM-7 cells and detection of GFP expression in these cells is technically challenging 
(personal communication with Dr. Brummelkamp).                                                          
 To distinguish whether there was a global problem with our gene trap viruses 
ability to infect KBM-7 cells from difficulty detecting mutagenesis using expression of 
the reporter gene, we isolated genomic DNA (gDNA) from KBM-7 cells infected with 
our retroviruses 1 week after infection and used PCR to determine whether the marker 
gene could be amplified. We were able to detect GFP in gDNA from cells infected with 
CMV-GFP (Fig. 3.6 lane 2) and GT-GFP (Fig. 3.6 lane 3) virus, but not in uninfected 
cells (Fig. 3.6 lane 1) or cells infected with GT-Puro virus (Fig. 3.6 lane 4). Interestingly, 
the signal from the CMV-GFP and GT-GFP viruses is similar. Our experiments with 
these retroviruses in Phoenix cells showed that the CMV-GFP virus is able to produce a 
strong GFP signal in the flow cytometry assay, yet in KBM-7 cells this expression is 
undetectable (Fig. 3.5). While the absolute value for infection is difficult to calculate, 
these experiments suggest that while the GT-GFP virus is competent to infect KBM-7 










                          
Figure 3.6: GFP is detectable in genomic DNA of transduced KBM-7 cells by PCR. PCR 
using primers specific to GFP was performed on genomic DNA prepared from KBM-7 
cells (lanes 1-4), GT-GFP plasmid (lane 5, positive control) or water (lane 6, no template 
control), run on an agarose gel and visualized using ethidium bromide. Lane 1: 
Uninfected cells. Lane 2: CMV-GFP virus infected cells. Lane 3: GT-GFP virus infected 







Insertional mutagenesis using retroviral transduction with gene trap plasmids has 
previously been performed in KBM-7 cells to identify host factors exploited by 
pathogens34. As insertion in a gene required for pathogen intoxication would lead to 
survival of the mutant cell, treatment of small pools of mutagenized cells with toxin for 
extended periods of time leads to survival of a single clone, which can be identified by 
sequencing. Our genetic screen was designed to identify genes required for NET 
formation. As such, insertions in genes required for NETosis would result in a reduction 
in extracellular DNA when stimulated with LPS and evaluated in our Picogreen plate 
assay. However, as not all cells in a population form NETs when stimulated5 (and Fig. 
3.2), treatment with agonist would not be lethal to the population. Therefore, our genetic 
screen depended on the ability to sort successfully mutagenized cells using either the 
puromycin resistance marker or the GFP marker and the ability of single KBM-7 cells to 
survive limited dilution cloning. These clones could then be assayed for NET formation 
and sequenced to determine genes where mutations disrupt NET formation. We 
determined that single KBM-7 cells were able to survive and grow as isolated clones 
(data not shown). In addition, amplification of gDNA from transduced cells showed 
detectable integration of both of our gene trap viruses. Unfortunately, selection using 
either puromycin resistance or GFP expression was unsuccessful. This was likely due to 
poor overall transduction efficiency, as our CMV-GFP virus also failed to demonstrate 
appreciable GFP expression in these cells.  
The Brummelkamp lab, who previously published work using KBM-7 cells in 
genetic screens, was kind enough to offer reagents and guidance throughout this project. 
 
80 
In personal communications, we were told that transduction of KBM-7 cells is 
technically challenging, and this is part of the reason that their lab has moved to 
screening for lethal phenotypes in pooled cells. Indeed, screening pools of cells for 
resistance to a lethal treatment has been very successful and identified several new genes 
important for intoxication41-43. Unfortunately, the conditions that would allow 100% of 
NET-competent cells to undergo NETosis have yet to be identified, and as such, our 
screen cannot be tailored to a pooled approach with current technology. Nevertheless, 
improvements in bioinformatics may allow our screen to be conducted as designed with a 
pooled approach in the future. For this to work, a pool of mutagenized cells would be 
treated with LPS to form NETs. The extracellular DNA would then be treated with 
DNase to fragment it, insertion sites would be pulled out and amplified using oligos 
specific to the insertions, amplified and subjected to deep sequencing. With sufficiently 
powerful bioinformatics tools, the extracellular DNA from the mutagenized cells could 
be compared to gDNA from the same cells. Insertions only found in gDNA but not in 
extracellular DNA would indicate genes that are required for NET formation. This kind 
of approach is beyond the reach of current bioinformatics, but may be feasible in the near 
future. 
Genetic screens offer the promise of an unbiased approach to discover novel 
biology. While the execution of the screen described here was limited by both our 
technical ability and current technology, these limitations are likely to be overcome in the 
near future and this screen can be revisited. Despite these setbacks, the observation that 
KBM-7 cells are capable of forming NETs is a novel one. As primary neutrophils are not 
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amenable to genetic manipulation in culture, KBM-7 cells may serve as a useful tool for 
studying NET formation in culture. 
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Current Review of Platelet Biology 
Platelets play a critical role in maintaining hemostasis, yet antiplatelet therapies 
are a booming industry1.  Platelet activation caused by atherosclerotic plaque rupture can 
rapidly lead to thrombus formation, occlusion of the vessel and hypoxia in downstream 
tissues. When this occurs in vessels supplying the heart, it results in myocardial 
infarction, the leading cause of death in the United States2. Antiplatelet therapy has 
reduced morbidity and mortality from cardiovascular disease over the last 50 years3, but 
comes at the risk of increased bleeding, which can be fatal4. A significant amount of 
research being conducted on platelets today aims to eliminate the risk of hemorrhage 
while effectively preventing platelet-dependent thrombus formation to treat 
cardiovascular disease. 
While their contributions to acute thrombus formation are widely acknowledged, 
a role for platelets in inflammation is emerging. Platelets rapidly release over 300 
preformed proteins from their granules upon activation, many of which function in 
thrombus formation and cell proliferation5. In addition, many proinflammatory cytokines 
are found in platelet releasates. CXCL4 and beta-thromboglobulin (β-TG) were some of 
the first chemokines identified, partly because the high concentrations of these proteins 
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released from platelets made them easy to purify6. While both of these proteins are 
known for their procoagulant properties7,8, they can also act on neutrophils to promote 
interaction with endothelial cells and the release of secondary granules,  and induce 
oxidative burst within monocytes9-11. CCL5 is also released from platelet granules, and 
has been shown to promote monocyte recruitment to inflamed endothelium in 
conjunction with CXCL4 as well as monocyte differentiation into foam cells12-14. 
Disruption of this interaction blocks monocyte recruitment to endothelium and attenuates 
atherosclerosis in mouse models15. 
Platelet granules are a heterogeneous mix of alpha granules, dense granules and 
lysosomes, each identified by specific subsets of proteins found within them16. Time-
lapse microscopy has shown that during platelet spreading, alpha granules expressing 
VAMP-3 move to a central granulomere region, while alpha granules expressing VAMP-
7 move to the periphery of the platelet17.  The differential sorting and release of subsets of 
granules suggests a regulated process. Given the role of platelets as rapid responders at 
sites of injury and their ability to regulate the inflammatory responses of other immune 
cells, it is possible that the differential release of subsets of platelet granules allows for 
fine regulation of immunologic responses.   
In addition to release of secreted molecules, granule fusion with the plasma 
membrane results in the translocation of receptors, such as P-selectin, to the platelet 
surface. P-selectin on the surface of platelets binds with PSGL-1 on leukocytes to 
promote adhesion to endothelium and trafficking to peripheral sites18-21. Heterotypic 
aggregates of activated platelets and leukocytes can also be found circulating in the 
peripheral blood, where they serve as markers of cardiovascular disease and induce 
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inflammatory responses22,23. Specifically, binding of platelet P-selectin to monocyte 
PSGL-1 is required for CCL5-dependent expression of inflammatory cytokines such as 
MCP-1 and IL-824, and IL-1β-dependent expression of COX-225 in monocytes. Platelet-
neutrophil interactions mediated by P-selectin result in neutrophil recruitment to the lung 
in acute lung injury and blockade of these interactions is capable of halting the 
development of acute lung injury in mouse models26. Platelet TLR4 activation induces 
platelet-neutrophil aggregation and NET formation  capable of trapping bacteria in the 
vasculature at the expense of endothelial damage27. Together, these studies indicate that 
interactions of platelets with immune effector cells are critical for host defense. 
While direct receptor-mediated interactions and release of granule contents allow 
platelets to affect localized responses, platelets can also release microparticles (MP), 
which are small membrane vesicles packaged with surface receptors, signaling proteins, 
mRNA, and miRNA capable of acting on distal target cells28,29. A variety of cells are 
capable of releasing MP, but in healthy individuals >90% of the plasma MP are platelet-
derived30. As MP display phosphatidylserine (PS) on their surface, they provide a 
platform for assembly of coagulation factors31,32 and many hemostatic-based diseases are 
associated with altered levels of MP33. The surface receptors found on MP are able to 
interact with target cells in a manner similar to that of the host cell, including P-selectin 
interactions with endothelium resulting in release of cytokines from the endothelium and 
expression of adhesion molecules34. Importantly, MP have been shown to deliver their 
protein, mRNA and miRNA to target cells and alter the functional responses of the 
recipient cells29,35. The degree to which this form of intercellular communication occurs in 
vivo and its functional relevance have not yet been determined. However, the easy 
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availability of platelets from phlebotomy makes them attractive candidates for 
manipulation and delivery of exogenous molecules to target cells. 
For small, anucleate cytoplasts, platelets contain an astonishing amount of 
molecular machinery. Prior to their release from megakaryocytes, proplatelets are 
packaged with pre-mRNA, mRNA and miRNA as well as the factors necessary for 
initiating regulated splicing, translation and functional miRNA regulation36-39. In response 
to activation, platelets have been shown to splice pre-mRNA for tissue factor and IL-1β 
to form mature message, resulting in increased protein expression and procoagulant 
responses39,40.  Platelets isolated from septic patients express spliced tissue factor mRNA, 
while healthy controls do not, suggesting that the regulated splicing of platelet pre-
mRNAs has functional consequences in disease states41. Platelets are also able to generate 
functional progeny in a process that resembles proplatelet formation from 
megakaryocytes, resulting in increased biomass in cultures42. This observation serves as a 
testament to the biosynthetic capacity of platelets and their broader potential to effect 
functional changes in healthy and diseased states. 
 
Platelets and eRNA 
Here, we have presented evidence for the first time that platelets are capable of 
sequestering exogenous RNA (eRNA). Uptake of eRNA does not require prior activation 
of platelets nor does it induce surface expression of P-selectin or activation of integrin 
αIIbβ3. Furthermore, platelets exposed to eRNA adhere normally and activate 
appropriately in response to thrombin. Taken together, these data suggest that eRNA 
uptake does not affect traditional platelet activation responses.  
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We observed the uptake of eRNA by platelets to be time- and concentration-
dependent, with a peak at 2h and a gradual decline overnight. In our initial studies we 
were surprised to find that eRNA rapidly (within 15ʹ) associates with platelet membranes, 
but only about 5% of this eRNA is ultimately internalized within the platelet and 
protected from ribonuclease treatment. When eRNA was incubated with monocytes or 
THP-1 cells it was rapidly degraded, suggesting that the eRNA sequestration we 
observed is unique to platelets. Using an in vitro transcribed (IVT) 5S-rRNA tagged with 
an RNA aptamer capable of binding a small molecule and emitting fluorescence43, we 
were able to visualize eRNA diffusely within unactivated platelets. Direct fluorophore-
conjugation of a longer IVT RNA demonstrated that eRNA localizes to the central 
granulomere region of spread platelets. We confirmed that platelets are capable of 
sequestering eRNAs of varying sizes and sequence, suggesting that the process is not 
dependent on a conserved secondary structure within the transcript. Identifying the 
mechanism by which platelets take up eRNA is of significant interest to us. In nucleated 
cells, scavenger receptors have been shown to participate in eRNA uptake44, and platelets 
are known to express the scavenger receptors CD36 and SR-BI45. Future studies in our 
lab will address the mechanism by which platelets sequester eRNA. 
 Despite introduction of a variety of eRNAs coding for proteins which we can 
readily assay for (RFP, luciferase, GM-CSF), we were unable to detect translation of 
eRNA in platelets under conditions tested. There are several possible explanations for 
this result. In nucleated cells, eRNA localizes within lysosomes and only a small fraction 
of internalized eRNA escapes the lysosome and is translated44. Despite the presence of 
functional translation machinery, platelet synthetic responses are much lower than those 
 
90 
of nucleated cells. If a large fraction of eRNA is sequestered within a lysosome-like 
compartment, we may be detecting transcript by RT-PCR that is unavailable for 
translation due to sequestration within a vesicle. Subsequently, if only a small fraction of 
this message is capable of escaping, the translational response of platelets may not be 
robust enough to yield detectable protein in our assays. Another possibility is that eRNA 
is sequestered in platelets and is only translated after platelets receive a secondary signal. 
Signal-dependent translation has been observed in platelets and represents an important 
mechanism by which platelets mediate inflammatory and prothrombotic processes40,46. 
We did not detect translation in thrombin-stimulated platelets, but it is possible that 
alternative signals could lead to translation of eRNA within platelets. Finally, it is 
possible that the relatively stable pool of eRNA detectable within platelets by RT-PCR is 
in fact partially degraded and unable to be translated into functional protein. While 
platelets are known to contain a variety of RNAs, the ability of platelets to degrade RNA 
has not been previously shown. To examine this possibility, we conducted preliminary 
experiments using radiolabeled IVT RNA incubated in the presence or absence of 
platelets or monocytes. RNA incubated with platelets was cut into several fragments of 
distinct sizes, >100bp each. It is likely that these fragments could represent a stable pool 
of template capable of generating a signal by RT-PCR, which nevertheless does not 
represent an intact message capable of being translated. However, a similar pattern was 
seen in the samples where RNA was incubated with monocytes, a condition where we do 
not see a signal by RT-PCR (data not shown). This result was confounding, and needs to 
be repeated with RT-PCR controls in tandem to allow for interpretation. Additionally, 
work will be done to determine whether the fragments we observe are generated by 
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sequence-specific cutting or by length and how long they remain within platelets.  
The central role that RNA serves in mammalian cells as a means to transmit 
sequence-specific information for translation can overshadow some of the more basic 
biochemical features of RNA. Detection of foreign material is an important part of innate 
immunity, and foreign RNA can be recognized by Toll-like receptors (TLR) -3 and -7 as 
well as RIG-I and Mda547. While platelets have been reported to express TLR-2, -4 and -
9, they are not known to express any of the receptors commonly known to respond to 
foreign RNA48,49. Nevertheless, the ability of platelets to robustly package and secrete MP 
raises the possibility that eRNA taken up by platelets is sequestered and then released in 
MP, which can interact with cells capable of inducing an immunologic response. We 
performed RT-PCR on MP isolated from platelets incubated with eRNA in the presence 
and absence of thrombin, but did not detect significant levels of eRNA released in MP. 
Importantly, RT-PCR of the platelet pellet showed that the bulk of the eRNA was 
sequestered and detectable using this assay demonstrating that the absence of a signal in 
the MP fraction is unlikely to be due to degradation of the template preventing detection. 
This suggests that platelets do not release sequestered eRNA in MP. Nevertheless, to rule 
out the possibility that partially degraded eRNA is released by platelet MP, radiolabeled 
template can be used to detect partially degraded RNA within a MP fraction. 
Extracellular RNA interactions with proteins have been shown to have important 
functions in hemostasis and thrombus formation. Specifically, RNA is able to bind VEGF 
and other growth factors with heparin-binding domains, resulting in increased endothelial 
cell permeability50,51. In addition, RNA promotes the activation of contact phase proteins, 
increasing their activity by 40-fold52,53. Administration of RNase (but not DNase) prior to 
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vascular injury in animal models reduces vessel occlusion and edema50. Our observations 
that platelets rapidly sequester eRNA could have two important physiological 
consequences in light of these reports. Upon traumatic injury to tissue, cells rupture and 
their cytoplasmic contents, including RNA, are released. The ability of platelets to 
rapidly sequester this released RNA may be important to prevent excessive coagulation 
responses and limit endothelial disruption. In addition, the RNA sequestered within 
platelets may be released under circumstances we have yet to identify, contributing to 
coagulation responses to maintain hemostasis. Our observation that the eRNA taken up 
by platelets is partially degraded would not affect its ability to function as a pro-
coagulant. 
The work presented here represents the first report that platelets sequester eRNA. 
We determined that uptake of eRNA is time- and concentration-dependent and does not 
depend on or result in platelet activation. The eRNA sequestered within platelets is not 
translated under conditions we have tested, and appears to be fragmented but not fully 
degraded. Future work will focus on determining the mechanisms responsible for platelet 
uptake of eRNA, the fate of the sequestered RNA and the contribution of eRNA to 
normal platelet functions. In addition, chemical modification of RNA has been shown to 
make it resistant to degradation, while allowing for translation54,55. We will explore this 
approach to generate functional proteins within platelets exposed to eRNA. This research 





Neutrophil Extracellular Traps: Then, Now and Tomorrow 
Upon their discovery, NETs were quickly appreciated for their role in 
contributing to host innate immune defense. Stimulation of NET formation was shown to 
promote killing of Staphylococcus aureus and Shigella flexneri56. While compelling, 
these initial studies were met with some skepticism. Neutrophil-mediated killing of these 
gram-negative and gram-positive pathogens is easily performed by phagocytosis and 
oxidative killing. It was difficult to understand why neutrophils would undergo a process 
that resulted in their demise when less radical means of defense are available. Subsequent 
studies demonstrated that NETs kill yeast in both the fungal and hyphal forms57. Hyphal 
yeast are too large to be engulfed by a single neutrophil, so it was thought that release of 
antimicrobial peptides was the primary means of host defense in this case58-60. The 
importance of NETs in defense against fungal pathogens was illustrated by a gene 
therapy study in a patient with chronic granulomatous disease (CGD) and a fulminant 
hyphal Aspergillus nidulans infection61. CGD patients have normal antimicrobial peptides 
and granule components, but a genetic defect in a subunit of the NADPH oxidase 
complex prevents oxidative burst as well as NET formation and results in patients with 
susceptibility to diverse pathogens62,63. Restoration of NADPH oxidase activity in this 
patient resulted in neutrophils that were now capable of forming NETs and clearance of 
the hyphal infection, a response which could be reversed in vitro when DNase was added 
to the system. Further supporting the role of NETs in normal host defense, it has been 
shown that neonatal neutrophils are unable to form NETs in response to agonists64. 
Neonates are known to have an incompletely characterized, multifactorial neutrophil 
dysfunction, which leaves them particularly vulnerable to infections, including life 
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threatening neonatal sepsis65. The defect in neonatal neutrophils preventing NET 
formation appears to be downstream of NADPH oxidase64, and further characterization of 
this pathway may result in treatments which restore NET formation and innate immune 
function in this vulnerable population.  
While the importance of NETs in innate immune defense is now widely accepted, 
it is also increasingly appreciated that NETs can contribute to disease. In mouse models 
of sepsis, NET formation has been shown to trap bacteria, but result in damage to the 
endothelium in liver sinusoids, possibly contributing to the decreased perfusion and end-
organ dysfunction seen in sepsis27. NETs have also been implicated in pathogen-
independent diseases such as transfusion related acute lung injury (TRALI), where 
markers of NET formation are elevated in the blood of TRALI patients66,67. In mouse 
models of TRALI, administration of DNaseI improves oxygen saturation and prevents 
neutrophil accumulation within the alveoli, suggesting that NETs contribute directly to 
disease pathogenesis. Tissue sections from the placenta of patients with preeclampsia 
show large numbers of NETs in the intervillous space that are not seen in normal 
placentas, and in vitro studies with placental-derived inflammatory factors are able to 
induce NET formation in culture68. NETs have also been implicated in the break in 
immunologic tolerance seen in the autoimmune disease systemic lupus erythematosus 
(SLE). SLE is an autoimmune disease characterized by B-cell production of antibodies 
against nuclear self-antigens (such as DNA and histones), chronic plasmacytoid dendritic 
cell (pDC) activation, immune complex formation and multiple organ dysfunction69. 
During NET formation, DNA forms complexes with antimicrobial peptides found within 
neutrophil granules before being released from the cell. Complexes of DNA with one of 
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these peptides, LL37, have been shown to break pDC tolerance to self DNA resulting in 
interferon production and the promotion of B-cell autoantibody production through TLR-
970,71. Surprisingly, serum from a subset of patients with SLE demonstrated a decreased 
ability to degrade NETs and activated complement deposition on NETs, which may 
promote autoantibody production72. Taken together, these studies underscore the need for 
exquisite control over NET formation and how an imbalance can result in life-threatening 
consequences.  
Our interest in developing a genetic screen to identify factors required for NET 
formation was precipitated by our incomplete understanding of the molecular process 
driving NET formation. Early studies demonstrated the requirement for ROS generation 
using small molecules as well as neutrophils from patients with CGD, which are 
incapable of generating ROS63. Additional experiments using mouse models, human 
variants and drugs established the role of neutrophil elastase, peptidylarginine deiminase 
4, mammalian target of rapamycin and myeloperoxidase in NET formation73-76. Despite 
such rapid progress, large gaps remain linking signaling events between pathogens, 
platelets and inflammatory cytokines and the complex process required to generate NETs.  
Using retroviral insertional mutagenesis in the mostly haploid human 
promyelocytic leukemia cell line, KBM-7, host factors required for pathogenesis and 
intoxication have been identified77-79. We demonstrated that KBM-7 cells are capable of 
forming NETs, a function which has only been reported in one other immortalized cell 
line to date80. We also successfully developed a plate-based assay to quantitate NET 
formation in mutagenized clones. Next, we set out to use gene-trap mutagenesis with the 
goal of generating a large pool of mutagenized KBM-7 cells, with successful insertion 
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into a coding gene resulting in expression of the reporter GFP. This would allow us to 
sort individual GFP-positive cells representing unique insertion events into 96-well plates 
using fluorescence-activated cell sorting and expand these clones in culture until there 
were sufficient cells to transfer to our plate-based assay and screen for NETs. Insertion 
into a gene required for NET formation would result in decreased signal in our NET 
assay. We would then sequence the insertion site to identify novel genes required for 
NETosis. Unfortunately, we were unable to develop conditions that allowed for 
successful transduction of KBM-7 cells with gene-trap retrovirus as detected by GFP 
expression.  
Upon close examination of the publications using KBM-7 cells to conduct genetic 
screens, it is clear that other researchers have focused their efforts on screens that rely on 
resistance to a lethal phenotype. While NETosis is a terminal process for the individual 
cell, only a subset of cells within a population generate NETs in response to agonist63. 
The reasons for this observation remain unclear, but we determined that it is not due to 
heterogeneity within the population, as limited dilution cloning does not produce clones 
capable of varying degrees of NETosis. Furthermore, prolonged culture in the presence of 
agonist does not result in a gradual decline in cell counts. As our screen depended on the 
ability to screen mutagenized cells using expression of the reporter rather than a lethal 
phenotype, we were unable to execute the screen as designed. 
Despite this setback, our interest in identifying novel genes required for NET 
formation remains. The first paper using KBM-7 cells in a genetic screen reported 
successful detection of GFP expression in mutagenized cells by flow cytometry. Our 
failure to detect GFP expression in KBM-7 cells mutagenized with the gene-trap virus as 
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well as a virus that induces constitutive expression of GFP from a CMV promoter 
suggests that our transduction efficiency was extremely low. In personal conversations 
with Dr. Brummelkamp, whose lab originally reported the use of these cells77, we were 
told that transduction of KBM-7 cells can be tricky. Using detailed protocols from the 
Brummelkamp lab we still failed to successfully detect GFP expression in our 
mutagenized cells, suggesting that additional optimization is necessary.  
Modifying our original screen design to allow for a pooled, rather than a 
subcloned, approach may also prove fruitful. Such a strategy would rely on powerful 
bioinformatics, but may be possible within the near future. The design of this screen 
would consist of mutagenesis of a pool of haploid cells, followed by removal of a fraction 
of these cells and genomic DNA isolation and analysis of insertion sites as a  reference 
population. Subsequently, the pool of mutagenized cells would be treated with agonist to 
induce NET formation, DNase would be added to digest the extracellular DNA, and 
insertion sites within the extracellular DNA would be mapped. Insertions in genes within 
the reference population which are not found within the extracellular DNA would suggest 
genes that are required for NET formation, and would be further analyzed in additional 
studies. As the bulk of insertion events are unlikely to affect NET formation, this 
approach amounts to searching for the proverbial needle in a haystack. Nevertheless, only 
a decade ago the sequence of the first complete human genome was published in a 
massive undertaking that took 13 years to complete81, and now companies advertise 
complete genome sequencing within a day for a $1,000. As the power to sequence and 
analyze large data sets improves, a pooled screen to identify factors required for NETosis 
may be similar to searching for a needle in a haystack with a metal detector. 
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Kindlins and Integrin Signaling 
The identification of mutations in the FERMT3 gene, coding for Kindlin-3, as the 
primary defect in all of the reported cases of LAD-III solved a long-standing question in 
the field of integrin biology82-86. Patients with LAD-III suffer from recurrent infections as 
well as a severe bleeding tendency, implicating a protein that is required for function of 
β1, β2 and β3 integrins87. Nevertheless, as integrins are required for cell-matrix 
interactions in cells throughout the body, the restriction of the LAD-III phenotype to 
hematopoietic cells suggested that this protein is expressed in a tissue-restricted fashion. 
Indeed, of the three members of the Kindlin family (Kindlin-1, -2 and -3) expressed in 
mice and humans, only Kindlin-3 expression is restricted to hematopoietic cells88 and 
deletion of kindlin-3 in mice phenocopies the defects seen in LAD-III patients89. 
Integrins are present as αβ heterodimers on the surface of cells, and require an 
intracellular signal to undergo a conformational change resulting in an active 
conformation capable of engaging ligand (inside-out signal)90. The intracellular tail 
domains of β integrins and the proteins they bind, including Talins and Kindlins, are 
necessary for this process91. While Talins bind a membrane proximal motif on β integrin 
tails, Kindlins have been shown to bind an identical motif on the distal tail89,92. Initially, it 
was unclear whether Kindlin served as a cofactor to recruit Talin to the plasma membrane 
or if it played a more direct role in activation of the integrin. Studies in Chinese hamster 
ovary cells using shRNA knockdown of Kindlin showed that loss of Kindlin prevented 
ligand binding but did not affect Talin recruitment to the membrane, suggesting that 
Kindlins are important coactivators of integrin signaling93. In addition, Kindlins link 
signals downstream of chemokine receptors to integrin activation to initiate inside-out 
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signaling94. Recent biochemical studies have demonstrated that several distinct regions 
within Kindlins are necessary for interactions with β integrins, phospholipid head groups 
within the plasma membrane and PIP3, and all are required for robust inside-out integrin 
signaling95-97.  
Kindlins have also been implicated in outside-in integrin signaling. Upon ligand 
binding, integrins transmit signals to the cytoskeleton and act on many intracellular 
signaling pathways important for development, leukocyte trafficking and hemostasis98. 
The role Kindlins play in inside-out signaling can be separated from outside-in signaling 
experimentally by bypassing inside-out signals pharmacologically or using constitutively 
active receptors. Several groups have shown defects in downstream integrin signaling in 
the absence of Kindlin, suggesting that Kindlins serve to transmit signals downstream of 
integrin activation to mediate outside-in signals99-102.  
The studies discussed above represent an aggregation of reports looking at 
Kindlin-1, Kindlin-2 and Kindlin-3 as well as a variety of integrin heterodimers. 
Nevertheless, both Kindlins and β integrin tails show a high degree of conservation 
within their respective families, suggesting that the broad concepts regarding function 
will be generally applicable and specificity will be achieved largely through ligand 
interactions and tissue-specific expression of additional binding partners91,103. The 
importance of Kindlins in integrin signaling is now widely accepted, and highlighted by 
the clinical defects seen in LAD-III patients. Our work demonstrating that the LAD-III 
index family we had previously identified had a mutation in FERMT3 that resulted in an 
absence of Kindlin-3 (Fig. 4.1) confirmed that defects in this protein are responsible for 










Figure 4.1: Kindlin-3 is absent in EBV-transformed lymphoblasts from Patient 1
86,104
. 
Lymphoblasts from Patient 1 and two control subjects were lysed, subjected to 






date are found throughout the gene and in genetically diverse patient backgrounds105.  
While key features of the LAD-III phenotype are shared between patients, there is 
variation in the severity and bony involvement106,107. Additional genetic modifiers may 




 In science, as in life, there is always more to be learned. The work presented here 
serves to illuminate previously unrecognized clinically-relevant biology, as well as gaps 
in our understanding of fundamental hematological processes for future research. Upon 
first glance, platelets appear to be simple anucleate cytoplasts with the singular function 
of maintaining hemostasis. However, closer examination reveals a complex capacity to 
integrate signals from diverse inputs and affect changes both autonomously and in 
conjunction with other cells within the hemostatic and immune continuum. Neutrophils 
were thought to have given up their secrets many decades ago, but recently revealed a 
new mechanism by which they protect the host from infection and contribute to 
inflammatory pathologies. The complexities of integrin signaling continue to provide 
insight into genetic diseases and new targets for therapeutics. The privilege and the 
responsibility of the researcher is to continue to ask questions in the face of answers, and 
to shine a light in the dark in search of answers to questions that have yet to be asked.  
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